,PageNo,Text
0,page_1,"['THE UNIVERSITY OF TEXAS', 'MD Anderson', 'Protocol Page', 'Cancer Center', 'A Phase II Single-arm Study of the Efficacy and Safety of Oral Rigosertib in Patients', 'with Myelofibrosis (MF) and Anemia', '2014-0546', 'Core Protocol Information', 'Short Title', 'Phase II Rigosertib in MF', 'Study Chair:', 'Jorge Cortes', 'Additional Contact:', 'Maria Rhona B. Pinsoy', 'Rachel R. Abramowicz', 'Leukemia Protocol Review Group', 'Additional Memo Recipients:', 'Recipients List', 'OPR Recipients (for OPR use only)', 'None', 'Study Staff Recipients', 'None', 'Department:', 'Leukemia', 'Phone:', '713-794-5783', 'Unit:', '428', 'Full Title:', 'A Phase II Single-arm Study of the Efficacy and Safety of Oral', 'Rigosertib in Patients with Myelofibrosis (MF) and Anemia', 'Protocol Type:', 'Standard Protocol', 'Protocol Phase:', 'Phase II', 'Version Status:', 'Activated 08/25/2017', 'Version:', '08', 'Document Status:', 'Saved as ""Final""', 'Submitted by:', 'Rachel R. Abramowicz--8/7/2017 2:47:00 PM', 'OPR Action:', 'Accepted by: Elizabeth Orozco -- 8/15/2017 3:09:53 PM', 'Which Committee will review this protocol?', 'The Clinical Research Committee (CRC)']"
1,page_2,"['Protocol Body', 'Development Phase:', 'Il', 'Product:', 'rigosertib sodium (ON 01910.Na), oral capsules', 'Principal Investigator:', 'Jorge Cortes, MD', 'Professor of Medicine, Department of Leukemia', 'UT MD Anderson Cancer Center', '1515 Holcombe Blvd, Unit 428', 'Houston, TX 77030', 'Email: jcortes@mdanderson.org', 'W', '2014-0546 Protocol Body CLEAN VERSION (08-07-17) docx']"
2,page_3,"['2014-0546', 'August 7, 2017', 'Page 1 of 49', 'CLINICAL STUDY PROTOCOL', 'A Phase II Single-arm Study of the Efficacy and Safety of Oral', 'Rigosertib in Patients with Myelofibrosis (MF) and Anemia', 'Development Phase:', 'II', 'Product:', 'rigosertib sodium (ON 01910.Na), oral capsules', 'Principal Investigator:', 'Jorge Cortes, MD', 'Professor of Medicine, Department of Leukemia', 'UT MD Anderson Cancer Center', '1515 Holcombe Blvd, Unit 428', 'Houston, TX 77030', 'Email: cortes@mdanderson.org', 'Supporter:', 'Onconova Therapeutics Inc.', '73 Route 31 North', 'Pennington, New Jersey 08534 (USA)', '1']"
3,page_4,"['2014-0546', 'August 7, 2017', 'Page 2 of 49', 'TABLE OF CONTENTS', 'TABLE OF CONTENTS', '2', 'LIST OF ABBREVIATIONS AND DEFINITION OF TERMS', '4', '1. INTRODUCTION', '8', '1.1. Description of the Investigational Product', '8', '1.2. Summary of Clinical Findings Relevant to the Trial', '8', '1.3. Summary of Potential Risks', '12', '1.4.', 'Study Rationale', '17', '2.', 'STUDY OBJECTIVES', '17', '3.', 'INVESTIGATIONAL PLAN', '17', '3.1.', 'Study Design', '17', '3.2. Selection of Study Population', '19', '3.2.1. Inclusion Criteria', '19', '3.2.2. Exclusion Criteria', '20', '3.3.', 'Removal of Patients from the Study', '21', '3.4.', 'Study Procedures', '21', '3.4.1. Efficacy Assessments', '22', '3.4.1.1.', 'Efficacy Outcomes', '22', '3.4.1.2.', 'Bone Marrow Examination and Cytogenetics', '22', '3.4.1.3.', 'Exploratory Genomics/Molecular Evaluation in Peripheral Blood', 'Samples', '23', '3.4.2. Safety Assessments', '23', '3.5. Treatments', '24', '3.5.1. Method of Assigning Patients to Treatment Groups', '24', '3.5.2. Treatments Administered', '24', '3.5.3. Management of Clinical Supplies', '25', '3.5.4. Rigosertib Dosing Adjustments', '26', '3.5.4.1.', 'Hematologic Toxicity', '26', '3.5.4.2.', 'Non-hematologic Toxicity - Hyponatremia', '26', '3.5.4.2.1. Treatment-related Urinary Symptoms', '26', '3.5.4.2.2. Treatment-related >Grade 2 Toxicity other than Urinary', 'Symptoms', '27', '3.5.5. Treatment Compliance', '27', '3.5.6. Management of Urinary Symptoms', '28', '3.5.7. Concomitant Therapy', '28']"
4,page_5,"['2014-0546', 'August 7, 2017', 'Page 3 of 49', '3.6. Statistical Methods', '28', '3.6.1.', 'Sample Size Considerations', '28', '3.6.2.', 'Analysis Populations', '29', '3.6.3. Final Analyses', '29', '3.6.3.1.', 'Efficacy Analyses', '29', '3.6.3.2.', 'Safety Analyses', '30', '3.6.3.3.', 'Additional Analyses', '30', ""4. INVESTIGATOR'S OBLIGATIONS"", '31', '4.1.', 'Reporting Adverse Events', '31', '4.1.1. Serious Adverse Event Reporting', '31', '4.1.2', 'Reporting Forms', '29', '4.2', 'Investigator Communications with Onconova', '29', '4.3', 'Pregnancies', '29', '5.', 'REFERENCE LIST', '33', '6.', 'APPENDICES', '35', 'Appendix 1: WHO Criteria for Diagnosis of Primary Myelofibrosis, Essential', 'Thrombocythemia, and Polycythemia Vera', '36', 'Appendix 2: 2008 IWG-MRT Diagnosis Criteria for Post-Polycythemia Vera and Post-', 'Essential Thrombocythemia Myelofibrosis', '38', 'Appendix 3: Eastern Cooperative Oncology Group (ECOG) Performance Status', '40', 'Appendix 4: 2013 IWG-MRT Revised Response Criteria for Myelofibrosis', '41', 'Appendix 5: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom', 'Score (MPN-SAF TSS)', '44', 'Appendix 6: Schedule of Events and Procedures', '44', 'Appendix 7: List of Clinical Laboratory Tests', '47', 'Appendix 8: List of Potential Substrates of CYP 2C8 and 2C9', '48', 'Appendix 9: List of Potential Inhibitors of P-gp', '49']"
5,page_6,"['2014-0546', 'August 7, 2017', 'Page 4 of 49', 'LIST OF ABBREVIATIONS AND DEFINITION OF TERMS', 'Abbreviation', 'Definition', 'ADL', 'Activities of daily living', 'ADR', 'Adverse drug reaction', 'AE', 'Adverse event', 'AKT', 'Serine-threonine kinase', 'ALT', 'Alanine transaminase', 'AML', 'Acute myeloid leukemia', 'ANC', 'Absolute neutrophil count', 'ASH', 'American Society of Hematology', 'AST', 'Aspartate transaminase', 'AUC0-a', 'Area under the plasma concentration-time curve from 0 to infinity', 'AZA', 'Azacitidine', 'BID', 'Twice daily', 'BM', 'Bone marrow', 'BMBL', 'Bone marrow blast', 'BMCR', 'Bone marrow complete response', 'BUN', 'Blood urea nitrogen', 'C1D1, C2D1', 'Cycle 1 Day 1, Cycle 2 Day 1', 'Cmax', 'Maximum plasma concentration', 'CBC', 'Complete blood count', 'CDC25', 'Cell division cycle 25', 'CDK', 'Cyclin-dependent kinase', 'CFR', 'Code of Federal Regulations', 'CI', 'Clinical improvement', 'CIV', 'Continuous intravenous', 'CRO', 'Contract research organization', 'CSR', 'Clinical study report', 'CT', 'Computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events']"
6,page_7,"['2014-0546', 'August 7, 2017', 'Page 5 of 49', 'Abbreviation', 'Definition', 'CYP', 'Cytochrome P450', 'DLT', 'Dose-limiting toxicity', 'ECG', 'Electrocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'Electronic case report form', 'EMH', 'Extramedullar hematopoiesis', 'EOS', 'End of study', 'EPO', 'Erythropoietin', 'ER', 'Erythroid response', 'ERES', 'Electronic Records/Electronic Signatures', 'ERK', 'Extracellular signal-regulated kinase', 'ESA', 'Erythropoiesis-stimulating agent', 'ET', 'Essential thrombocythemia', 'FAS', 'Full analysis set', 'FDA', 'Food & Drug Administration', 'FISH', 'Fluorescent in-situ hybridization', 'GCP', 'Good clinical practice', 'G-CSF', 'Granulocyte colony-stimulating factor', 'GI', 'Gastrointestinal', 'GM-CSF', 'Granulocyte-macrophage colony-stimulating factor', 'Hgb', 'Hemoglobin', 'HIV', 'Human immunodeficiency virus', 'HMA', 'Hypomethylating agent', 'hr', 'Hour', 'IB', ""Investigator's brochure"", 'ICF', 'Informed consent form', 'ICH', 'International Conference on Harmonisation', 'Int-1', 'Intermediate-1', 'IPSS', 'International Prognostic Scoring System']"
7,page_8,"['2014-0546', 'August 7, 2017', 'Page 6 of 49', 'Abbreviation', 'Definition', 'IRAE', 'Immediately Reportable Adverse Event', 'IRB', 'Institutional Review Board', 'IV', 'Intravenous', 'IWG-MRT', 'International Working Group for Myelofibrosis Research and', 'Treatment', 'JAK2', 'Janus kinase 2', 'LCM', 'Left coastal margin', 'LDH', 'Lactate dehydrogenase', 'MAPK', 'Mitogen-activated protein kinase', 'MDS', 'Myelodysplastic syndromes', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MF', 'Myelofibrosis', 'MFSAF', 'Myelofibrosis self assessment form', 'MRI', 'Magnetic resonance imaging', 'MTD', 'Maximum tolerated dose', 'NCI', 'National Cancer Institute', 'NHLBI', 'National Heart Lung and Blood Institute', 'ON 01910.Na', 'rigosertib sodium (rigosertib); sodium salt of (E)-2,4,6-', 'trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl', 'sulfone', 'os', 'Overall survival', 'PB', 'Peripheral blood', 'PD', 'Progressive disease', 'P-gp', 'P-glycoprotein', 'PI3K', 'Phosphatidylinositol-3 kinase', 'PK', 'Pharmacokinetic', 'PLK', 'Polo-like kinase', 'PLT', 'Platelet', 'PMF', 'Primary myelofibrosis']"
8,page_9,"['2014-0546', 'August 7, 2017', 'Page 7 of 49', 'Abbreviation', 'Definition', 'PP', 'Per protocol', 'PRBC', 'Packed red blood cells', 'PT', 'Preferred Term (MedDRA)', 'PV', 'Polycythemia vera', 'Q3W', 'Every 3 weeks', 'Q6W', 'Every 6 weeks', 'QC', 'Quality control', 'QOL', 'Quality of life', 'QW', 'Every week', 'RAEB, - -1, -2', 'Refractory anemia with excess blasts, -type 1, -type 2', 'RBC', 'Red blood cell', 'RBD', 'Ras binding domain', 'RPTD', 'Recommended Phase II dose', 'SADR', 'Serious adverse drug reaction', 'SAE', 'Serious adverse event', 'SC', 'Subcutaneous(ly)', 'SOC', 'System Organ Class (MedDRA)', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'Tmax', 'Time to maximum plasma concentration', 'TEAE', 'Treatment-emergent adverse event', 'TI', 'Transfusion independence', 'ULN', 'Upper limit of normal', 'US', 'United States', 'UTI', 'Urinary tract infection', 'WBC', 'White blood cell', 'WHO', 'World Health Organization']"
9,page_10,"['2014-0546', 'August 7, 2017', 'Page 8 of 49', '1.', 'INTRODUCTION', '1.1.', 'Description of the Investigational Product', 'Rigosertib sodium (ON 01910.Na; rigosertib hereafter) is a first-in-class dual', 'phosphatidylinositol 3-kinase (PI3K)/polo-like kinase (PLK) pathway inhibitor that targets critical', 'signals involved in the growth and survival of cancer cells. At the molecular level, rigosertib acts', 'by selectively targeting 2 of the PI3K subunits (a and ÃŸ), while also inhibiting downstream signals', 'in the pathway such as the phosphorylation of serine-threonine kinase (AKT) and translation of', 'cyclin D1 (Prasad 2009, Olnes 2012). Rigosertib also acts by inhibiting the PLK pathway, leading', 'to a reduction in the activity of pro-mitotic proteins such as cell division cycle 25 (CDC25) and', 'cyclin-dependent kinase (CDK)/cyclin B (Jimeno 2010). The dual molecular mechanism of action', 'of rigosertib results in induction of multiple centrosomes during cell division, leading to multi-', 'polar spindle formation (Reddy 2008), total disorganization of the mitotic apparatus causing', 'chromosomal catastrophe (Reddy 2008), and modulation of the extracellular signal-regulated', 'kinase (ERK)/mitogen-activated protein kinase (MAPK) (growth) and AKT (survival) pathways,', 'promoting cell death (apoptosis) in cancer cells (Chapman 2012). Recent data suggest that', 'rigosertib binds to the Ras binding domain (RBD) of Ras effector proteins (ie, PI3K and Raf),', 'thereby leading to their inactivation (data on file). This novel mechanism may help explain the', 'multi-faceted effects of rigosertib, such as inhibition of the PI3K and PLK pathways.', 'Rigosertib was granted orphan drug status for the treatment of MDS by the Office of Orphan', 'Products Development (HF-35) at the Food & Drug Administration (FDA) on September 3, 2009', '(designation request #09-2894).', '1.2.', 'Summary of Clinical Findings Relevant to the Trial', 'Two formulations of rigosertib are currently being studied: intravenous (IV) and oral. At the time', ""of the latest compilation of information (Investigator's Brochure [IB] edition 21; Rigosertib IB),"", '1176 patients with either MDS or other hematologic malignancies (N = 661) or advanced cancer', 'and solid tumors (N = 515) were enrolled in 26 Phase I-III clinical studies of IV (N = 839) and', 'oral (N = 337) rigosertib conducted by Onconova. Six other Phase I studies of rigosertib in a', 'total of 51 patients with MDS and other hematologic malignancies were completed or are being', 'conducted by other Sponsors (NHLBI and SymBio Pharmaceuticals) under different INDs.', 'In Phase I/II studies of IV rigosertib in adult patients with MDS and acute myeloid leukemia', '(AML), rigosertib was administered as 2- to 6-day continuous intravenous (CIV) infusions.', 'Overall, rigosertib was reasonably well tolerated (see Rigosertib IB). Significant activity in', 'reducing bone marrow blasts (BMBL) was found to be correlated to overall survival (OS).']"
10,page_11,"['2014-0546', 'August 7, 2017', 'Page 9 of 49', 'A Phase I dose escalation study of oral rigosertib in MDS patients was completed at Moffitt Cancer', 'Center and Columbia University Medical Center (#09-01). The study was divided into 3 parts:', 'Part I evaluated the bioavailability and tolerability of single oral doses (70 mg, 140 mg, 280 mg,', '560 mg, and 700 mg) administered weekly for 5 weeks. Part II (maximum tolerated dose [MTD]', 'evaluation) assessed the tolerability of the same oral escalating doses (ie, 70 mg, 140 mg, 280 mg,', '560 mg, and 700 mg), administered twice daily (BID) for 14 days of a 21-day cycle. Part III was', 'a confirmation of the recommended Phase II dose (RPTD) with absolute bioavailability and food', 'effect studies. Eligibility criteria included any International Prognostic Scoring System (IPSS)', 'MDS risk group with at least 1 cytopenia; failure to respond to at least 1 prior standard treatment;', 'Eastern Cooperative Oncology Group (ECOG) performance status 2; and adequate kidney and', 'liver functions. Key exclusion criteria included hypoplastic MDS (< 10% cellularity), ascites,', 'history of seizures, uncontrolled hypertension, and history of human immunodeficiency virus', '(HIV) infection. Dose-limiting toxicity (DLT) was defined as > Grade 3 non-hematologic drug-', 'related toxicity (based on National Cancer Institute [NCI] Common Terminology Criteria for', 'Adverse Events [CTCAE]) or delay in recovery of blood counts to Baseline levels for more than', '30 days in the absence of response. A total of 37 MDS patients were enrolled. Pharmacokinetic', '(PK) dose proportionality was established in the 70 mg to 700 mg single-dose range in the first', '3 patients enrolled, and pharmacodynamically active concentrations were reached. During the', 'subsequent escalation phase, the RPTD was identified as 560 mg BID.', 'Overall rigosertib capsules were reasonably well tolerated, with dysuria as the most frequent', 'treatment-emergent adverse event (TEAE). One patient on 700 mg experienced 2 DLTs (dysuria', 'and shortness of breath) during the first 3-week cycle. Another patient on 700 mg experienced', 'Grade 3 dysuria during Cycle 2.', 'Twelve patients in the confirming cohort underwent full PK evaluation (absolute bioavailability', 'vs. the IV formulation, and food effect). Following a single fasting dose, oral rigosertib was rapidly', 'absorbed (time to maximum plasma concentration [Tmax] ~ 1 hr). Systemic exposure, as', 'determined by maximum plasma concentration (Cmax) and the area under the plasma concentration-', 'time from 0 to infinity (AUC0-00), increased in a linear and dose-proportional manner over the dose', 'range of 70 mg to 700 mg. The plasma concentration-time profile exhibited a rapid distribution', 'phase followed by a slower elimination phase. The elimination half-life from plasma after oral', 'rigosertib dosing was comparable to estimates obtained after IV dosing. The absolute', 'bioavailability of rigosertib (560 mg dose) was 35%. Food significantly reduced the rate and extent', 'of rigosertib absorption. Oral administration of rigosertib after a meal decreased Cmax and AUC0-', '00 by 77% and 61%, respectively, compared to fasting conditions, with an estimated bioavailability', 'of 14%.', 'Encouraging signs of activity were observed. Two bone marrow complete responses (BMCR) were', 'observed in refractory anemia with excess blasts type 1 (RAEB-1) patients previously treated with', 'azacitidine (AZA) at the 140 mg and 560 mg dose levels. In addition, transitions to transfusion']"
11,page_12,"['2014-0546', 'August 7, 2017', 'Page 10 of 49', 'independence (TI) and erythroid response (ER) were observed in a subgroup of 16 patients with', 'Low/intermediate-1 (Int-1) transfusion-dependent MDS patients in the 560 mg and 700 mg', 'cohorts. Of the 12 evaluable patients treated for at least 8 weeks (of which 10 were in the 560 mg', 'group), TI (defined as no red blood cell [RBC] transfusions needed over a period of 8 consecutive', 'weeks) occurred in 4 patients, all in the 560 mg cohort. Erythropoiesis-stimulating agents (ESA)', 'were administered before or after the onset of TI, suggesting a possible synergy between rigosertib', 'and ESA for patients receiving ESA before the onset of TI. Duration of TI varied from 8 weeks to', 'more than 47 weeks, with an onset of TI between Week 3 and Week 10. One additional patient in', 'the 560 mg cohort had an ER, defined as reduction of at least 4 units of transfused RBC over', '8 weeks.', 'The Phase II trial (09-05) is designed to evaluate oral rigosertib as a single agent in transfusion-', 'dependent, lower-risk MDS patients. This trial is a randomized, 2-arm study of oral rigosertib,', 'which was administered initially as 560 mg BID continuously. The 560 mg BID continuous', 'regimen was changed to an intermittent 2-weeks on/1-week off regimen after 9 patients were', 'enrolled, due to an excess of urinary side effects. The 560 mg BID intermittent regimen was further', 'reduced to 560 mg in the morning and 280 mg in the afternoon to try and further minimize adverse', 'urinary effects. This intermittent reduced regimen resulted in a much improved urinary tolerability,', 'particularly the absence of Grade 3 urinary toxicity. The study was then amended to a', '560 mg/280 mg continuous regimen. In the study, transfusion-dependent patients must have', 'received at least 4 units of RBC transfusions over 8 weeks before randomization and can receive', 'transfusions and ESA while on study.', 'Enrollment of 57 patients from 5 clinical sites in Study 09-05 was completed on November 5,', '2013. Interim results are available and were reported during the annual meeting of the American', 'Society of Hematology (ASH) in New Orleans in December 2013 (Raza 2013).', 'Of the 36 evaluable patients on intermittent dosing (of which 35 were receiving the original', '560 mg BID regimen and 1 the reduced 560/280 mg regimen) treated for at least 8 consecutive', 'weeks, 14 (39%) achieved TI (no RBC transfusion for at least 8 consecutive weeks) lasting from', '8 weeks to 73 weeks (median not reached) (see Figure 1). Of the 9 patients who received', 'continuous dosing, of which 8 were treated for at least 8 weeks, 2 achieved TI, the first for', '10 weeks and the second for more than 18 weeks. In addition, 4 patients with > Grade', '3', 'neutropenia at Baseline (absolute neutrophil count [ANC] values < 1.0 K/L) had neutrophil', 'improvement for at least 8 weeks. One patient achieved a minor ER (transfusion decrease of 4 units', 'RBC over 8 weeks).']"
12,page_13,"['2014-0546', 'August 7, 2017', 'Page 11 of 49', 'Figure 1', 'Transfusion Independence in 14 of 36 Evaluable Patients (39%) Treated for at Least', '8 Weeks with Intermittent Rigosertib Regimen (Original or Reduced)', '01-01', '01-20', '01-35', '01-25', '01-14', '01-23', '01-27', 'Patient ID', '01-39', '01-37', '01-02', '01-34', '01-45', '01-41', '01-10', 'o', '10', '20', '30', '40', '50', '60', '70', '80', 'Duration of Transfusion Independence (weeks)', 'Overall oral rigosertib was reasonably well tolerated with the exception of urinary side effects.', 'The most frequent adverse events (AEs) in the 560 mg BID continuous dosing arm (> 20% of', 'patients) were nausea, dysuria, pollakiuria, and urinary tract infection (UTI) (33% each), and', 'cystitis, hematuria, micturition urgency, diarrhea, oedema peripheral, and pyrexia (22% each). The', 'most frequent AEs in the 560 mg BID intermittent dosing arm (> 20% of patients) were pollakiuria', '(51%), fatigue (40%), micturition urgency and urinary tract pain (34% each), hematuria and', 'dysuria (31% each), constipation (26%), nausea and UTI (23% each), and diarrhea (20%). There', 'was a clinically significant reduction of urinary events in patients receiving the 560/280 mg', 'intermittent regimen: the most frequent AE to date in this arm (> 20% of patients) is fatigue (31%).', 'The following urinary events were observed in 1 patient each: nocturia, pollakiuria and UTI.', 'In the group receiving the continuous regimen, 2 patients (22%) developed Grade 3 cystitis,', '1 patient each (11%) developed Grade 3 hematuria and Grade 3 UTI. The incidence of Grade 3', 'urinary events seemed to be reduced when patients were administered the original intermittent', 'regimen (6% of patients each with Grade 3 cystitis, Grade 3 UTI and Grade 3 urinary tract pain,', 'and 11% of patients with hematuria). No patients receiving the reduced intermittent regimen', 'developed Grade 3 urinary events to date. The only Grade 3 AE in that group was progression to', 'AML in 1 patient.', 'The causality of urinary side effects is being investigated. Since no nephrotoxicity was evident and', 'significant urinary excretion of unmetabolized drug was noted, it was hypothesized that the', 'residence time of rigosertib in the urinary bladder was a mitigating factor in causing irritation or', 'inflammation of the bladder epithelia. Limited cystoscopy and other observations supported this', 'hypothesis and lead to an improvement program based on hydration, bicarbonate tablets as needed,', 'and judicious dose reduction. In general, symptoms can be relieved or reduced by these', 'approaches.']"
13,page_14,"['2014-0546', 'August 7, 2017', 'Page 12 of 49', 'Final study results are pending.', '1.3.', 'Summary of Potential Risks', ""The Reference Safety Information for this study is in the latest Rigosertib's IB A summary of"", 'expected drug-related treatment-emergent adverse events (AEs) in studies of oral rigosertib is', 'presented below (Table 1).']"
14,page_15,"['2014-0546', 'August 7, 2017', 'Page 13 of 49', 'Table 1', 'Reference Safety Information (RSI)', 'Summary of Expected Drug-related Treatment-emergent Adverse Events by Preferred Term, Sorted by Frequency, in Studies of Oral Rigosertib', 'Safety-Evaluable (N=337)', 'Rigosertib Integrated Analysis', 'MedDRA Preferred Term [1][2]', 'Any Grade', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Dysuria', '103 (30.6%)', '35 (10.4%)', '61 (18.1%)', '7 (2.1%)', '0', '0', 'Pollakiuria', '67 (19.9%)', '25 (7.4%)', '42 (12.5%)', '0', '0', '0', 'Haematuria', '62 (18.4%)', '27 (8.0%)', '25 (7.4%)', '10 (3.0%)', '0', '0', 'Micturition urgency', '43 (12.8%)', '20 (5.9%)', '22 (6.5%)', '1 (0.3%)', '0', '0', 'Fatigue', '40 (11.9%)', '18 (5.3%)', '19 (5.6%)', '3 (0.9%)', '0', '0', 'Nausea', '39 (11.6%)', '27 (8.0%)', '9 (2.7%)', '3 (0.9%)', '0', '0', 'Urinary tract pain', '31 (9.2%)', '11 (3.3%)', '18 (5.3%)', '2 (0.6%)', '0', '0', 'Diarrhoea', '28 (8.3%)', '19 (5.6%)', '8 (2.4%)', '1 (0.3%)', '0', '0', 'Urinary tract infection', '27 (8.0%)', '3 (0.9%)', '21 (6.2%)', '3 (0.9%)', '0', '0', 'Decreased appetite', '18 (5.3%)', '15 (4.5%)', '2 (0.6%)', '1 (0.3%)', '0', '0', 'Cystitis', '17 (5.0%)', '2 (0.6%)', '8 (2.4%)', '7 (2.1%)', '0', '0', 'Constipation', '13 (3.9%)', '11 (3.3%)', '2 (0.6%)', '0', '0', '0', 'Neutropenia', '10 (3.0%)', '0', '1 (0.3%)', '1 (0.3%)', '8 (2.4%)', '0', 'Vomiting', '10 (3.0%)', '8 (2.4%)', '1 (0.3%)', '1 (0.3%)', '0', '0', 'Nocturia', '9 (2.7%)', '3 (0.9%)', '6 (1.8%)', '0', '0', '0', 'Abdominal pain', '8 (2.4%)', '7 (2.1%)', '1 (0.3%)', '0', '0', '0', 'Hyponatraemia', '8 (2.4%)', '4 (1.2%)', '0', '4 (1.2%)', '0', '0', 'Proteinuria', '8 (2.4%)', '2 (0.6%)', '4 (1.2%)', '2 (0.6%)', '0', '0', 'Thrombocytopenia', '8 (2.4%)', '1 (0.3%)', '0', '2 (0.6%)', '5 (1.5%)', '0', 'Dyspepsia', '7 (2.1%)', '6 (1.8%)', '1 (0.3%)', '0', '0', '0', 'Headache', '7 (2.1%)', '5 (1.5%)', '2 (0.6%)', '0', '0', '0', 'Urinary incontinence', '7 (2.1%)', '0', '7 (2.1%)', '0', '0', '0', 'Neutrophil count decreased', '6 (1.8%)', '0', '0', '0', '6 (1.8%)', '0']"
15,page_16,"['2014-0546', 'August 7, 2017', 'Page 14 of 49', 'Table 1', 'Reference Safety Information (RSI)', 'Summary of Expected Drug-related Treatment-emergent Adverse Events by Preferred Term, Sorted by Frequency, in Studies of Oral Rigosertib', 'Safety-Evaluable (N=337)', 'Rigosertib Integrated Analysis', 'MedDRA Preferred Term [1][2]', 'Any Grade', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Abdominal discomfort', '5 (1.5%)', '3 (0.9%)', '2 (0.6%)', '0', '0', '0', 'Anaemia', '5 (1.5%)', '3 (0.9%)', '0', '2 (0.6%)', '0', '0', 'Cystitis noninfective', '5 (1.5%)', '3 (0.9%)', '2 (0.6%)', '0', '0', '0', 'Dysgeusia', '5 (1.5%)', '5 (1.5%)', '0', '0', '0', '0', 'Aspartate aminotransferase increased', '4 (1.2%)', '4 (1.2%)', '0', '0', '0', '0', 'Chromaturia', '4 (1.2%)', '4 (1.2%)', '0', '0', '0', '0', 'Flatulence', '4 (1.2%)', '4 (1.2%)', '0', '0', '0', '0', 'Abdominal distension', '3 (0.9%)', '2 (0.6%)', '1 (0.3%)', '0', '0', '0', 'Abdominal pain upper', '3 (0.9%)', '1 (0.3%)', '2 (0.6%)', '0', '0', '0', 'Alanine aminotransferase increased', '3 (0.9%)', '1 (0.3%)', '2 (0.6%)', '0', '0', '0', 'Blood bilirubin increased', '3 (0.9%)', '3 (0.9%)', '0', '0', '0', '0', 'Platelet count decreased', '3 (0.9%)', '0', '0', '1 (0.3%)', '2 (0.6%)', '0', 'Urinary hesitation', '3 (0.9%)', '0', '3 (0.9%)', '0', '0', '0', 'Urinary retention', '3 (0.9%)', '3 (0.9%)', '0', '0', '0', '0', 'Bladder irritation', '2 (0.6%)', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', 'Bladder spasm', '2 (0.6%)', '2 (0.6%)', '0', '0', '0', '0', 'Blood urine present', '2 (0.6%)', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', 'Confusional state', '2 (0.6%)', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', 'Frequent bowel movements', '2 (0.6%)', '2 (0.6%)', '0', '0', '0', '0', 'Leukopenia', '2 (0.6%)', '0', '0', '1 (0.3%)', '1 (0.3%)', '0', 'Lymphocyte count decreased', '2 (0.6%)', '2 (0.6%)', '0', '0', '0', '0', 'Malaise', '2 (0.6%)', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', 'White blood cell count decreased', '2 (0.6%)', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', 'Bladder pain', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', '0']"
16,page_17,"['2014-0546', 'August 7, 2017', 'Page 15 of 49', 'Table 1', 'Reference Safety Information (RSI)', 'Summary of Expected Drug-related Treatment-emergent Adverse Events by Preferred Term, Sorted by Frequency, in Studies of Oral Rigosertib', 'Safety-Evaluable (N=337)', 'Rigosertib Integrated Analysis', 'MedDRA Preferred Term [1][2]', 'Any Grade', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Bowel movement irregularity', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Leukocyturia', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Liver function test abnormal', '1 (0.3%)', '0', '0', '1 (0.3%)', '0', '0', 'Lymphopenia', '1 (0.3%)', '0', '0', '1 (0.3%)', '0', '0', 'Mental status changes', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Neutropenic sepsis', '1 (0.3%)', '0', '0', '1 (0.3%)', '0', '0', 'Polyuria', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Red blood cells urine', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', '0', 'Red blood cells urine positive', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', '0', 'Urethral pain', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Urge incontinence', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', '0', 'Urine analysis abnormal', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Urine flow decreased', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Urine output decreased', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'White blood cells urine positive', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', '[1] Number of Patients used as denominator to calculate percentages.', '[2] Patients with multiple TEAEs were only counted once within a summary category: preferred term, maximum grade, or relationship to treatment. Treatment-Emergent Adverse', 'Events (TEAEs) were defined as all AEs that occurred after the first dose of study medication or within 30 day post-treatment period. MedDRA version 17.0.', 'Studies include 09-01, 09-02, 09-03, 09-04, 09-05, 09-07, 09-08, 09-09 and 09-12.']"
17,page_18,"['2014-0546', 'August 7, 2017', 'Page 16 of 49', 'Based on nonclinical studies, the following effects could potentially be observed:', 'Decrease in spleen or thymus weight;', ""In men, reduction in sperm cell count and/or decrease of testicles' weight that could lead"", 'to infertility, and/or a decrease in the size of the prostate gland; these effects were', 'partially or completely reversible in animals.', 'Fetotoxicity (lower fetal weight) and teratogenicity (increased incidence of primarily', 'craniofacial malformations); no maternal toxicity was observed in animals;', 'Rigosertib was found to be an inhibitor or a substrate of the following transporters, which', 'has the potential to lead to drug-drug interactions. Caution should be exercised and dose', 'adjustments of the concomitant substrate or inhibitor drugs should be considered when', 'dosing concurrently with rigosertib (see list of drugs that are substrates or inhibitors of', 'these transporters at: FDA Guidance DDI).', 'Inhibition of CYP isoform 2C9 in vitro at clinically relevant concentrations.', 'Additional in vitro studies to determine the effect of plasma protein binding', 'showed that, when rigosertib was incubated with cryopreserved human', 'hepatocytes in 100% human plasma to determine its potential for inhibition of', 'CYP2C9, the potency of rigosertib decreased by 2.74-fold (12.5 M) relative to', 'that measured in the absence of protein. Based on these data, rigosertib has the', 'potential for drug-drug interaction (DDI) with CYP2C9;', 'Time-dependent inhibition of CYP isoform 2C8. However, additional in vitro', 'studies to determine the effect of plasma protein binding showed that, in the', 'presence of plasma, the potency of rigosertib to inhibit CYP2C8 was very low', '(IC50 > 300 M). Based on these data, rigosertib does not have the potential for', 'DDI with CYP2C8;', 'Inhibition of OAT3, OATP1B1, and OATP1B3 at clinically relevant', 'concentrations. Rigosertib could impair the excretion of co-medications that are', 'known substrates of these transporters;', 'Rigosertib was found to be a substrate (but not an inhibitor) of P-gp and BCRP.', 'Co-medications that are known inhibitors of these transporters should be taken', 'with caution, as they could impair the hepatic excretion of rigosertib', 'Rigosertib is 98% protein bound and should be administered with caution to', 'patients who are taking concomitant medications that are also highly protein', 'bound (eg, warfarin).', 'There was no evidence of ocular or cutaneous phototoxicity in female pigmented rats', 'after 3 consecutive daily IV administrations of rigosertib with single solar-simulated', 'ultraviolet radiation exposure simultaneously during the final administration.', 'Based on all clinical and nonclinical data available to date, and evaluating the frequency of', 'reported events, the following are considered potential risks: Urinary disorders; Hyponatremia;', 'pulmonary alveolar haemorrhage/respiratory distress; Hepatic effects; Central nervous system']"
18,page_19,"['2014-0546', 'August 7, 2017', 'Page 17 of 49', '(CNS) effects; Effects on spermatogenesis; Thymus involution; Teratogenicity/fetotoxicity;', 'Potential carcinogenicity; and Retroperitoneal fibrosis have been identified as potentially', 'important risks. The risk of phototoxicity was ruled out based on lack of evidence in animal', 'studies but ongoing monitoring via routine proactive pharmacovigilance continues. Informed', 'consents are being revised as needed to incorporate all the new potentially important risks. After', 'evaluating the evidence in animal studies and the frequency of reporting in the clinical studies,', 'the following AEs were deleted from this list: gallbladder hyperplasia, diabeltes insipidus, and', 'phototoxicity. These events occurred in less than 0.1% of exposed patients and are unlikely to be', 'risks associated with Rigosertib.', '1.4.', 'Study Rationale', 'Strong erythroid activity of oral rigosertib has been observed in lower-risk transfusion-dependent', 'MDS patients (Section 1.2) treated with oral rigosertib. As 45% of patients receiving ruxolitinib', 'experience Grade 3 or 4 anemia, it is hypothetized that oral rigosertib may improve anemia post-', 'ruxolitinib.', 'In addition, Janus kinase 2 (JAK2) allelic reduction has been described in 1 patient in Study 04-05', 'conducted at Mount Sinai School of Medicine. This patient had MDS with evidence of', 'myelofibrosis (MF) treated initially with AZA for 4 years. Splenomegaly, which was present at', 'the outset of treatment, resolved completely. The patient was positive for presence of the', 'JAK2 V617F mutation prior to the start of IV rigosertib. The JAK 2-positive allele burden was', 'reduced by 41% between Cycle 2 and Cycle 4, suggesting that rigosertib could have activity in MF.', '2.', 'STUDY OBJECTIVES', 'The primary objective of this study is to assess, in patients with myelofibrosis and anemia, the', 'efficacy of oral rigosertib in improving anemia and symptoms, and in decreasing the spleen size', 'of those patients with splenomegaly.', 'This study will also assess the safety and tolerability of oral rigosertib in this patient population.', '3.', 'INVESTIGATIONAL PLAN', '3.1.', 'Study Design', 'This is planned as a Phase II, 2-stage, single-arm study. Up to 35 evaluable patients with MF and', 'anemia will receive oral rigosertib BID daily, on a continuous basis (see Study Design in Figure 2).', 'Patients will take 560 mg rigosertib (two 280 mg capsules) twice daily in fasting conditions (see', 'fasting instructions in Section 3.5.2). To be evaluable, patients need to be treated for at least', '24 weeks with oral rigosertib.']"
19,page_20,"['2014-0546', 'August 7, 2017', 'Page 18 of 49', 'In the first stage, a total of 18 evaluable patients will be enrolled. If 2 or fewer responses are', 'observed in the first 18 evaluable patients, the trial may terminate for futility. Otherwise, an', 'additional 17 evaluable patients will be enrolled in the second stage. A summary of the composite', 'response (as defined in Section 3.6.1) of the first 18 subjects should be submitted to the IND', 'Medical Monitor before moving to the second phase of enrollment.', 'At least 7 responses in 35 evaluable patients treated for at least 24 weeks with oral rigosertib are', 'required to confirm a 30% target response rate at a significance level of 0.05 (see Section 3.6.1,', 'Sample Size Considerations).', 'Figure 2', '2014-0546 Design', 'Screening', 'Treatment for up to 48 weeks', 'Endpoints:', 'Patients with', 'Oral rigosertib, fasting conditions', 'Anemia', 'MF + anemia', '560 mg morning/560 mg afternoon,', 'response', 'continuously', 'Symptoms', 'response', 'Spleen', 'N=35', 'response', 'evaluable', 'All study participants will be allowed, as medically justified, access to RBC and platelet (PLT)', 'transfusions, and to filgrastim (granulocyte colony-stimulating factor, [G-CSF]). Rigosertib dosing', 'adjustment policies are described in Section 3.5.4.', 'Patients will remain treated on study for 48 weeks or until progressive disease (PD) criteria', 'according to 2013 revised International Working Group for Myelofibrosis Research and Treatment', '(IWG-MRT) response criteria (Appendix 4) are met, unacceptable toxicity is observed,', ""intercurrent illness or a change in the patient's condition prevents further administration of study"", 'drug treatment, or until death from any cause occurs, whichever comes first. Patients who have', 'decreased splenomegaly and/or improvement of anemia and/or improvement in', 'Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF']"
20,page_21,"['2014-0546', 'August 7, 2017', 'Page 19 of 49', 'TSS) scoring of at least 50% (see Appendix 5) may continue to be treated in the study beyond', '48 weeks until progression or until death from any cause, whichever comes first.', '3.2.', 'Selection of Study Population', 'The diagnosis of MF will be based on bone marrow (BM) aspirate and/or biopsy performed within', '6 weeks prior to Screening. Measurement of JAK2 V617F allele burden in BM samples, if not', 'done within 6 months prior to Screening, must be provided with the Screening BM biopsy/aspirate', 'report.', '3.2.1.', 'Inclusion Criteria', 'Male and female patients who meet all of the following criteria are eligible for enrollment in the', 'trial:', 'a. >18 years of age;', 'b. Diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera (post-PV) MF or', 'post-essential thrombocythemia (post-ET) MF based on the World Health Organization', '(WHO) criteria (Appendix 1) or the IWG-MRT criteria (Appendix 2), which must be', 'confirmed by BM aspirate and/or biopsy within 6 weeks prior to Screening. Measurement', 'of JAK2 V617F allele burden in BM samples, if not done within 6 months prior to', 'Screening, must be provided with the Screening BM biopsy/aspirate report (patients are', 'eligible regardless of JAK2 mutation status);', 'c. Anemia or RBC-transfusion dependence defined as follows:', 'a. Anemia: defined for the purpose of this protocol as 1) a hemoglobin level <10 g/L', 'on every determination over 84 days before study-entry, without RBC-transfusions,', 'or 2) a hemoglobin level <10 g/L on a patient that is receiving RBC-transfusions', 'periodically but not meeting criteria for transfusion-dependent patient as defined', 'below. The baseline hemoglobin value for these subjects is the lowest hemoglobin', 'level during the antecedent 84 days.', 'b.', 'RBC-transfusion-dependence: RBC-transfusion-frequency of>/=2 units PRBC/28', 'days averaged over 84 days immediately pre-study-entry. There must not be any', 'consecutive 42 days without an RBC-transfusion during this interval.', 'd. ECOG performance status of 0, 1 or 2 (see Appendix 3);', 'e. Willing to adhere to the prohibitions and restrictions specified in this protocol (Notation:', ""the subject's willingness to adhere to prohibitions and restrictions must be clearly"", 'communicated in the on-study note.);', 'f. The patient must signed an informed consent form (ICF) indicating that s/he understands', 'the purpose of, and procedures required for, the study and is willing to participate.']"
21,page_22,"['2014-0546', 'August 7, 2017', 'Page 20 of 49', '3.2.2.', 'Exclusion Criteria', 'Patients with any of the following will not be enrolled in the study:', 'a. Ongoing clinically significant anemia due to factors such as known iron, vitamin B12, or', 'folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI) bleeding;', 'b. Serum ferritin < 50 ng/mL;', 'c.', 'Any active malignancy within the past year, except basal cell or squamous cell skin cancer', 'or carcinoma in situ of the cervix or breast; patients with history of prior malignancies', 'should be free of disease for at least 3 years to be eligible for this study;', 'd. Uncontrolled intercurrent illness, including, but not limited to symptomatic congestive', 'heart failure, unstable angina pectoris, or cardiac arrhythmia;', 'e.', 'Active infection not adequately responding to appropriate therapy;', 'f.', ""Direct bilirubin > 2.0 mg/dL not related to hemolysis or Gilbert's disease;"", 'g. Alanine transaminase (ALT) or aspartate transaminase (AST) > 2.5 x the upper limit of', 'normal (ULN);', 'h. Serum creatinine > 2.5 mg/dL;', 'i. Ascites requiring active medical management including paracentesis;', 'j.', 'Hyponatremia (defined as serum sodium level < 130 mEq/L);', 'k. Female patients who are pregnant or lactating;', '1.', 'Patients of childbearing potential (ie, women of childbearing potential and men with female', 'partners of childbearing potential) who are unwilling to follow strict contraception', 'requirements (including 2 reliable methods in combination: 1 non-hormonal, highly-', 'reliable method [diaphragm, condoms with spermicidal foam or jelly, or sterilization] plus', '1 additional reliable method [birth control pills, intrauterine device, contraceptive', 'injections, or contraceptive patches]) before entry and throughout the study, up to and', 'including the 30-day non-treatment follow-up period;', 'm. Female patients of childbearing potential who have a positive blood or urine pregnancy test', 'at Screening;', 'n. Major surgery without full recovery or major surgery within 3 weeks of Screening;', 'o. Uncontrolled hypertension (defined as a sustained systolic pressure > 160 mmHg and/or a', 'diastolic pressure > 110 mmHg);', 'p. New onset seizures (within 3 months prior to Screening) or poorly controlled seizures;', 'q. Any other concurrent investigational agent or chemotherapy, radiotherapy, or', 'immunotherapy;', 'r.', 'Chronic use (> 2 weeks) of corticosteroids (prednisone >/= 10 mg/24 hr equivalent) within', '4 weeks of Screening;', 'S.', 'Investigational therapy within 2 weeks of Screening;']"
22,page_23,"['2014-0546', 'August 7, 2017', 'Page 21 of 49', 't.', ""Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or"", 'comply with study requirements.', '3.3.', 'Removal of Patients from the Study', 'Patients will be discontinued in the following circumstances:', 'a. The patient dies;', 'b. There is evidence of clinically significant PD according to 2013 revised IWG-MRT criteria', '(Appendix 4);', 'c. There is no clinical improvement (CI) or anemia response per 2013 revised IWG-MRT', 'criteria (Appendix 4) after 48 weeks of treatment;', 'd. The Investigator decides that the patient should be withdrawn from the study. If this', 'decision is due to a serious adverse event (SAE) or a clinically significant abnormal', 'laboratory value, the study drug must be discontinued and appropriate measures taken. The', 'MD Anderson IND Office must be notified immediately;', 'e. The patient or attending physician requests that the patient be withdrawn from the study;', 'f.', 'The MD Anderson IND Office, the supporter or a regulatory agency for any reason,', 'terminates the study;', 'g. The patient develops unstable ascites requiring medical management including', 'paracentesis;', 'h. The patient has bilateral Grade 4 edema (per CTCAE) with 10% increase in body weight;', 'i.', 'The drug exhibits unacceptable toxicity;', 'j. The patient becomes pregnant or fails to use adequate birth control (for those patients of', 'childbearing potential);', 'k. Non-compliance to condom use for male patients;', '1. The patient exhibits a pattern of non-compliance with study procedures;', 'm. The patient is lost to follow-up. In such a case, every possible effort must be made by the', 'study site personnel to contact the patient and determine the reason for discontinuation.', 'The measures taken to contact the patient must be documented.', '3.4.', 'Study Procedures', 'The schedule of events and study procedures is detailed in tabular form in Appendix 6.', ""Each study procedure should be performed on the day dictated by the patient's dosing schedule."", 'However, if a patient is unable to have a study procedure performed on the scheduled day, the', 'procedure must be performed within the particular visit window; otherwise it will be considered a']"
23,page_24,"['2014-0546', 'August 7, 2017', 'Page 22 of 49', ""missed procedure. Since significant failure to comply may result in the patient's being withdrawn"", 'from the study, repeated deviations from visit windows should be discussed with theMD Anderson', 'IND Office.', '3.4.2.', 'Efficacy Assessments', '3.4.2.1. Efficacy Outcomes', 'The following outcomes will be assessed:', 'Symptoms response, as determined by change in QOL score before Week 48, using the', 'MPN-SAF TSS (Appendix 5);', 'Spleen response at Week 24 and Week 48 (defined as > 35% spleen volume reduction from', 'Baseline, which must be confirmed by MRI or CT measurement; see 2013 revised', 'IWG-MRT response criteria for MF in Appendix 4);', 'Duration of spleen response;', 'Anemia response (see 2013 revised IWG-MRT response criteria for MF in Appendix 4)', 'including change in Hgb and PRBC units transfusion requirements;', 'Change in PLT count and PLT transfusion requirements;', 'BM aspirate and/or biopsy at Week 24 and Week 48 to assess MF and measure', 'JAK2 V617F allele burden;', 'OS at Week 48.', '3.4.2.2. Bone Marrow Examination and Cytogenetics', 'The percentage of BMBL will be quantified by morphology assessment of a specimen of BM', 'aspirated smear (Wright-Giemsa stained) and/or biopsy (Hematoxylin-Eosin stained). If the', 'proportion of BMBL is estimated as an interval (eg, 5% to 10% BMBL), then the interval mean', 'value (ie, 7.5% in this example) will be used for BMBL evaluation. Automated quantification of', 'CD34+ blasts by flow cytometry method will not routinely be used for quantification of BMBL.', 'However, if the BM is too fibrotic to get a satisfactory BM aspirate, then quantification of BMBL', 'using CD34 immunostaining on BM biopsy may be performed.', 'Cytogenetic analysis will be performed using the fluorescent in-situ hybridization (FISH)', 'technique or the conventional G-banding technique (20-metaphases method).', 'Optional exploratory evaluations of genomics and proteomics exploring pathways potentially', 'involved in the pathogenesis of MF and response to treatment will be carried out in BM samples', 'collected before and during treatment.']"
24,page_25,"['2014-0546', 'August 7, 2017', 'Page 23 of 49', 'Leftover blood and BM samples will be used for this testing. No additional samples will be', 'collected.', '3.4.2.3. Exploratory Genomics/Molecular Evaluation in Peripheral Blood', 'Samples', 'Optional genomic and molecular evaluations exploring pathways potentially involved in the', 'pathogenesis of MF and response to treatment may be carried out in aliquots of peripheral blood', '(PB) samples, which will be refrigerated and processed.', 'Leftover blood and BM samples will be used for this testing. No additional samples will be', 'collected.', '3.4.3.', 'Safety Assessments', 'Specific safety parameters and procedures will include recording of medical history, medication', 'history, and concomitant medications, physical examination, measurement of vital signs (blood', 'pressure, temperature, respiration rate, and pulse), weight, standard 12-lead ECG at Screening,', 'laboratory evaluations, and toxicity and AE assessments. Adverse events will be graded according', 'to the NCI Common Terminology Criteria Version 4 (CTCAE v4). Adverse events will be', 'recorded from the time of the first protocol-specific intervention up to 30 days after last dose of', 'rigosertib.', 'Safety assessments will include the collection of AEs reported by the patient or observed by the', 'Investigator or study site personnel. Questions should be of a general nature and should not suggest', 'symptoms. Patients should be asked whether, since the time of the last observation or visit, any of', 'the following occurred:', 'They experienced any changes in well-being;', 'They used any new medications;', 'They changed medication regimens (both prescription and over-the-counter);', 'They were hospitalized or had any accidents.', 'When an AE is suspected, all relevant evaluations will be carried out and appropriate treatment', ""provided. Additional follow-up will be performed as necessary and recorded in the patient's source"", 'documents, with the results provided to theMD Anderson IND Office. Patients who experience', 'any clinically significant AEs will remain under medical supervision until the Investigator or the', 'MD Anderson IND Office deems the AE to be resolved, stabilized, or no longer serious enough to', 'warrant follow-up. Laboratory values that are abnormal and not assessed as AEs may be followed', 'at the discretion of the Investigator or the MD Anderson IND Office until resolved or stabilized.', 'For AE definitions and reporting requirements, refer to Section 4.1.']"
25,page_26,"['2014-0546', 'August 7, 2017', 'Page 24 of 49', '3.5.', 'Treatments', '3.5.1.', 'Method of Assigning Patients to Treatment Groups', 'This is a Phase II, 2-stage, single-arm study. Up to 35 evaluable patients with MF and anemia will', 'be enrolled. To be evaluable, patients need to be treated for at least 24 weeks with oral rigosertib.', 'Outside Physician Participation During Treatment', '1. MDACC Physician communication with the outside physician is required prior to the', 'patient returning to the local physician. This will be documented in the patient record', ""2. A letter to the local physician outlining the patient's participation in a clinical trial will"", ""request local physician agreement to supervise the patient's care (Appendix E)"", '3. Protocol required evaluations outside MDACC will be documented by fax. Faxed', 'evaluations will be dated and signed by the MDACC physician/investigator indicating that', 'they have reviewed it.', '4. A copy of the informed consent, protocol abstract, treatment schema and evaluation', 'during treatment will be provided to the local physician.', '5. Documentation to be provided by the local physician will include progress notes,', 'reports of protocol required laboratory and diagnostic studies and documentation of any', 'hospitalizations.', '6. The home physician will be requested to report to the MDACC physician/investigator', 'all life threatening events within 24 hours of documented occurrence.', '7. Changes in drug dose and/or schedule must be discussed with and approved by the', 'MDACC physician investigator, or their representative prior to initiation, and will be', 'documented in the patient record.', '3.5.2.', 'Treatments Administered', 'Rigosertib will be supplied as 280 mg and 70 mg capsules by Onconova. Study drug must be stored', ""between 2Â°C and 8Â°C (ie, refrigerated), protected from light, whether at the patient's home or at"", 'the institution.', 'Rigosertib will be administered daily, continuously, on an outpatient basis. Patients will take', '560 mg rigosertib in the morning (two 280 mg capsules) and 560 mg rigosertib in the afternoon.']"
26,page_27,"['2014-0546', 'August 7, 2017', 'Page 25 of 49', 'See Section 3.5.4 for adjusted rigosertib dose regimens. Treatments should be started within 2', 'weeks of completion of screening and meeting eligibility criteria.', 'Patients should be instructed to take rigosertib in a fasting state BID as follows:', 'The morning dose should be taken after an overnight fast, on an empty stomach, and', 'patients should wait 1 hr after dosing to have breakfast.', 'The afternoon dose should be taken at approximately 3 PM (1 hr) at least 2 hr after lunch,', 'on an empty stomach, and patients should wait 1 hr before the next meal.', 'Water is permitted during the fasting period. Any vomited dose will be reported as a missed dose.', 'Good hydration (ie, at least 2 liters of water per day) is recommended for all patients.', '3.5.3. Management of Clinical Supplies', 'The Investigator will have overall responsibility for the use of the study medication. Under no', 'circumstances will the Investigator allow rigosertib to be used other than as directed by this', 'protocol. The Investigator or designee will provide a signed acknowledgment for receipt of the', 'study medications and a signed acknowledgment for return of study medication containers and', 'unused study medication at the end of the study. An accurate record of the dispensing of all study', 'medication must be maintained. Upon completion or termination of the study, remaining study', 'drug will be returned to Onconova, unless otherwise instructed by the MD Anderson IND Office', 'or Onconova.', 'Qualified study center personnel must receive study drug deliveries, record the receipt, and assure', 'that the study drug is handled and stored safely and properly. The packing list must be reconciled', 'against the bottles received. Any extra/damaged drug product containers will be destroyed at the', 'site according to local procedures, or sent to Onconova for destruction, as instructed and', 'documented by Onconova.', 'Study drug must be stored between 2Â°C and 8Â°C (ie, refrigerated), protected from light, whether', ""at the patient's home or at the institution."", 'Copies of all dispensing records for the study drug must be kept at the study center as part of', 'required study documentation. At the end of the study, the study center must be able to reconcile', 'delivery records with records of study drug received, dispensed, and returned. The Investigator', 'must account for any discrepancies.', 'Rigosertib may not be relabeled or reassigned for use. Rigosertib may not be used for any purposes', 'other than what is outlined in this protocol, including other human studies, animal investigations,', 'or in vitro testing.']"
27,page_28,"['2014-0546', 'August 7, 2017', 'Page 26 of 49', '3.5.4.', 'Rigosertib Dosing Adjustments', 'The number of capsules to be taken as a function of adjusted dose is presented in Table 2.', 'Table 2', 'Rigosertib Dosing Adjustments', 'Original Dose', 'First Dose', 'Second Dose', 'Third Dose Reduction', 'Reduction', 'Reduction', 'Morning dose', '560 mg', '560 mg', '420 mg', '280 mg', '(Two 280 mg', '(Two 280 mg', '(One 280 mg + two', '(One 280 mg capsule)', 'capsules)', 'capsules)', '70 mg capsules)', 'Afternoon', '560 mg', '280 mg', '210 mg', '140 mg', 'dose', '(Two 280 mg', '(One 280 mg', '(Three 70 mg', '(Two 70 mg capsules)', 'capsules)', 'capsule)', 'capsules)', '3.5.4.1. Hematologic Toxicity', 'If ANC and/or PLT nadir are decreased by 50% from Baseline count and to > Grade 3 levels', 'unrelated to disease, comorbidities or concomitant medications, the next rigosertib dose may be', 'delayed until the ANC has increased to > 1 X 109/L and the PLT count has increased to', '> 75 X 109/L. If the next dose has to be delayed by more than 14 days after the last dose, rigosertib', 'will be restarted at the next lower dose level (see Table 2). If the delay is 14 days after the last', 'dose, rigosertib may be restarted at 100% of scheduled dose. Patients who experience treatment-', 'related neutropenia and/or thrombocytopenia of 6 weeks duration or more (consecutive) in more', 'than two occasions may continue on study (after appropriate dose adjustments as per Table 2) only', 'after discussion with the IND office to justify the appropriateness of continued therapy.', '3.5.4.2. Non-hematologic Toxicity - Hyponatremia', 'If a patient develops > Grade 3 hyponatremia, rigosertib will not be administered until resolution', 'to Grade 2 and serum and urine osmolality, serum albumin, BUN, serum creatinine, and serum', 'and urinary sodium will be measured to assist in the medical management of hyponatremia.', 'Additional tests may be carried out as clinically warranted.', '3.5.4.2.1. Treatment-related Urinary Symptoms', 'If any treatment-related urinary symptoms of Grade 2 or higher in severity that are at least 1 grade', 'higher than Baseline, develop during the treatment period, treatment will be withheld until', 'resolution to Grade 1 or Baseline status and resumed using the schedule displayed in Table 3.']"
28,page_29,"['2014-0546', 'August 7, 2017', 'Page 27 of 49', 'Table 3', 'Oral Rigosertib Step-by-step Dose Reductions for Urinary Toxicity', 'Episodes of', 'Starting Dose', 'Dose Adjustment', 'Urinary Toxicity', 'Morning', 'Afternoon', 'Morning', 'Afternoon', '1', '560 mg', '560 mg', '560 mg', '280 mg', '2', '560 mg', '280 mg', '420 mg', '280 mg', '3', '420 mg', '280 mg', '420 mg', '210 mg', '4', '420 mg', '210 mg', '280 mg', '210 mg', '5', '280 mg', '210 mg', '280 mg', '140 mg', '6', '280 mg', '140 mg', '140 mg', '140 mg', '7', '140 mg', '140 mg', '140 mg', '70 mg', '8', '140 mg', '70 mg', '70 mg', '70 mg', '9', '70 mg', '70 mg', '140 mg every other day', '0 mg', 'Should a further episode of urinary toxicity occur, the patient will be withdrawn from the trial and', 'followed.', '3.5.4.2.2. Treatment-related >Grade 3 Toxicity other than Urinary Symptoms', 'If any treatment-related non-hematologic toxicity of Grade 3 or higher is present on the day of', 'administration of rigosertib:', '1. Rigosertib treatment will be withheld until resolution to Grade 1 or Baseline toxicity', 'grading, whichever is greater, then dosing will be resumed at full dose;', '2. If the same treatment-related toxicity of Grade 2 or higher reoccurs, rigosertib dosing will', 'be reduced (see Table 2) at the next administration;', '3.', 'If the same treatment-related non-hematologic toxicity of > Grade 2 reoccurs, rigosertib', 'dose will be reduced further (see Table 2) after resolution to Grade 1 or Baseline status;', '4. If the same toxicity persists and is not tolerable, the patient will be withdrawn from the', 'study.', '3.5.5. Treatment Compliance', ""Each dose of rigosertib should be administered on the day dictated by the patient's dosing schedule."", 'Patients should not take missed doses. Patients will be given a diary to document compliance with', 'study drug.']"
29,page_30,"['2014-0546', 'August 7, 2017', 'Page 28 of 49', '3.5.6.', 'Management of Urinary Symptoms', 'Good hydration (ie, at least 2 liters of water per day) is recommended for all patients. If dysuria', 'develops, the following therapies may be prescribed:', 'Sodium bicarbonate tablets if the patient is not on a sodium-restricted diet: 650 mg tablets', 'given BID with two 8-ounce glasses of water 1 hr after rigosertib administration;', 'Pyridium if the patient has a normal creatinine value and is not allergic to phenazopyridine:', '100 mg 3 times daily orally, taken with a full glass of water and food; pyridium should not', 'be taken for more than 2 days.', 'Please refer to Section 3.5.4.2.1 for dosing adjustments in case of > Grade 2 urinary toxicity.', '3.5.7.', 'Concomitant Therapy', 'All concomitant medications (including non-prescription drugs and herbal therapies) received', ""from 30 days prior to study entry until the end of study will be recorded in the patient's chart. The"", 'information should include the name of the drug, indication, daily dose with units, and the start', 'and stop date(s) of administration.', 'All patients may be transfused when judged to be medically necessary by the Investigator. The', 'date and type of transfusion, the Hgb and/or PLT values prior to transfusion (obtained at the time', 'of type/cross match), and the number of units transfused must be recorded on the eCRF. The reason', 'for transfusion should also be documented.', 'Recombinant G-CSF or granulocyte-monocyte colony stimulating factor (GM-CSF) can be used', 'as clinically indicated (e.g., for Grade 3 or 4 neutropenia with recurrent or resistant bacterial', 'infections). Recommended dosage for G-CSF is 5 g/kg subcutaneous (SC) daily (NCCN 2011).', 'Based on findings from nonclinical studies, rigosertib inhibits CYP isoforms 2C9 and 2C8 in vitro', 'at clinically relevant concentrations. Caution should be exercised and dose reduction of the', 'concomitant substrate drugs should be considered when dosing rigosertib concurrently with', 'medications with narrow therapeutic range that are substrates of CYP2C9 or CYP2C8 (see', 'Appendix 8). In addition, rigosertib was found to be a P-gp substrate, but not a P-gp inhibitor (see', 'list of potential P-gp inhibitors in Appendix 9).', '3.6.', 'Statistical Methods', 'This study is a Phase II, proof-of-concept, single-arm study of the efficacy and safety of oral', 'rigosertib in patients with MF and anemia.', '3.6.1.', 'Sample Size Considerations', 'The primary endpoint will be the proportion of patients achieving spleen response by Week 24 or', 'Week 48 (defined as > 35% spleen volume reduction from Baseline, which requires confirmation']"
30,page_31,"['2014-0546', 'August 7, 2017', 'Page 29 of 49', 'by MRI or CT; see 2013 revised IWG-MRT criteria in Appendix 4) and/or anemia response by', 'Week 24 or Week 48 (defined as the proportion of transfusion-independententententententententententententententententententententententententententent patients with Hgb', 'increase of at least 2 g/dL from Baseline or the proportion of transfusion-dependent patients', 'becoming transfusion independent for at least 12 weeks as defined in 2013 IWG-MRT criteria;', 'Appendix 4) and/or symptoms response (defined as the proportion of patients achieving > 50%', 'reduction in the MPN-SAF TSS score; see Appendix : at any time before Week 48. These', 'response criteria will be referred to as ""composite response"".', 'A response rate (composite response described above) of 30% or more is considered clinically', 'meaningful, against a minimal or ""uninteresting"" response rate of 10% or less. A Simon 2-stage', 'optimal design is used in order to minimize the expected sample size if the regimen has low', 'activity. If there are 2 or fewer responses in the first 18 evaluable patients, the trial may terminate', 'for futility. Otherwise, 17 more evaluable patients will be enrolled, for a total of 35 evaluable', 'patients. At least 7 responses in 35 evaluable patients are required to confirm the 30% target', 'response rate at a significance level of 0.05, assuming a power of 0.90. Probability of termination', 'at Stage 1 is 73% and 6% for underlying responses rates of 10% and > 30%, respectively.', 'Descriptive statistics (mean, standard deviation, and coefficient of variation, median, minimum', 'and maximum) will be calculated for safety and efficacy parameters.', '3.6.2.', 'Analysis Populations', 'The analyses will be done on the 3 following populations:', 'The full analysis set (FAS) population will include all patients enrolled and treated.', 'The per-protocol (PP) population will include all patients who complete the study without', 'major protocol violations and are treated for a minimum of 24 weeks.', 'The safety population will include all patients who received at least 1 dose of rigosertib. It', 'is identical to the FAS population.', '3.6.3.', 'Final Analyses', '3.6.3.1. Efficacy Analyses', 'Analyses of the primary and secondary efficacy outcomes will be performed on the FAS and PP', 'populations.', 'The primary endpoint will be the proportion of patients with splenomegaly at Baseline achieving', 'spleen response at Week 24 or Week 48 (defined as > 35% spleen volume reduction from Baseline,', 'which requires confirmation by MRI or CT; see 2013 revised IWG-MRT criteria in Appendix 4)', 'and/or anemia response at Week 24 or Week 48 (defined as the proportion of transfusion-', 'independent patients with Hgb increase of at least 2 g/dL from Baseline or the proportion of']"
31,page_32,"['2014-0546', 'August 7, 2017', 'Page 30 of 49', 'transfusion-dependent patients becoming transfusion independent for at least 12 weeks as defined', 'in 2013 IWG-MRT criteria; Appendix 4) and/or symptoms response (defined as the proportion of', 'patients achieving > 50% reduction in the MPN-SAF TSS score; see Appendix 5) at any time', 'before Week 48.', '3.6.3.2. Safety Analyses', 'Safety analyses will be performed on the safety population. Safety definitions are found in', 'Section 4.1.', 'Adverse Events:', 'Adverse events will be coded using the most recent version of the Common Terminology Criteria', 'for Adverse Events v4 (CTCAE). Adverse events will be summarized by patient, not by event.', 'Investigators will be asked to assess the relationship of AEs to study drug. The relationship of each', 'AE to study drug will be categorized as not related, unlikely related, possibly related, probably', 'related, or definitely related to study drug.', 'Disease progression will not be considered an AE.', 'A listing of all AEs will be provided using the most recent version of CTCAE and will include', '(but will not be limited to) onset and resolution dates, seriousness, severity, relationship, action', 'taken with study drug, and outcome. Adverse Events (AEs) will be evaluated according to', 'current CTC version in each protocol. Only unexpected and related AEs will be recorded in', 'the Case Report Form (CRF). Appendix D ""Leukemia Specific AE Recording Guidelines"" will', 'be followed.', 'Deaths:', 'The number of patients who died will be summarized. A by-patient listing of deaths including', 'death date, cause of death, number of days from first and last dose of rigosertib, and relationship', 'to study drug will also be provided.', 'Laboratory Assessments:', 'Laboratory test data may be analyzed using summary statistics on changes from Baseline or', 'distributions of worst on-study laboratory values based on CTCAE grade.', 'Vital Signs:', 'Vital signs may be analyzed using summary statistics on changes from Baseline or distribution of', 'worst on-study values based on CTCAE grade.', '3.6.3.3. Additional Analyses']"
32,page_33,"['2014-0546', 'August 7, 2017', 'Page 31 of 49', 'ECOG Performance Status:', 'ECOG performance status has integer values from 0 (fully active) to 4 (completely disabled) (see', 'Appendix 3). The number and percentage of patients with each result for the latest pre-enrollment', 'examination will be summarized. For each patient, the best post-screening ECOG performance', 'status (lowest score) will be summarized over the entire time on study. A shift table will be', 'presented indicating the change from baseline ECOG status to maximum ECOG for the entire time', 'on study. Graphical displays may be generated if appropriate.', 'Population Pharmacokinetics:', 'Blood samples for measurement of rigosertib will be taken in all patients 1 hr after rigosertib', 'administration on Baseline/C1D1 visit (morning dose), and at predose and 1 hr after rigosertib', 'administration on Day 28 (+/-5 days) (morning dose). Population PK analyses will consider', 'relationships between mean blood levels of rigosertib and the efficacy outcomes.', '4.', ""INVESTIGATOR'S OBLIGATIONS"", '4.1.', 'Reporting Adverse Events', '4.1.1.', 'Serious Adverse Event Reporting', 'An adverse event or suspected adverse reaction is considered ""serious"" if, in the view of either the', 'investigator or the sponsor, it results in any of the following outcomes:', 'Death', 'A life-threatening adverse drug experience - any adverse experience that places the patient,', 'in the view of the initial reporter, at immediate risk of death from the adverse experience', 'as it occurred. It does not include an adverse experience that, had it occurred in a more', 'severe form, might have caused death.', 'Inpatient hospitalization or prolongation of existing hospitalization', 'A persistent or significant incapacity or substantial disruption of the ability to conduct', 'normal life functions.', 'A congenital anomaly/birth defect.', 'Important medical events that may not result in death, be life-threatening, or require hospitalization', 'may be considered a serious adverse drug experience when, based upon appropriate medical', 'judgment, they may jeopardize the patient or subject and may require medical or surgical', 'intervention to prevent one of the outcomes listed in this definition. Examples of such medical', 'events include allergic bronchospasm requiring intensive treatment in an emergency room or at', 'home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the', 'development of drug dependency or drug abuse (21 CFR 312.32).']"
33,page_34,"['2014-0546', 'August 7, 2017', 'Page 32 of 49', 'Important medical events as defined above, may also be considered serious adverse events.', 'Any important medical event can and should be reported as an SAE if deemed appropriate', 'by the Principal Investigator or the IND Sponsor, IND Office.', 'All events occurring during the conduct of a protocol and meeting the definition of a SAE', 'must be reported to the IRB in accordance with the timeframes and procedures outlined in', '""The University of Texas M. D. Anderson Cancer Center Institutional Review Board', 'Policy for Investigators on Reporting Unanticipated Adverse Events for Drugs and', 'Devices"". Unless stated otherwise in the protocol, all SAEs, expected or unexpected, must', 'be reported to the IND Office, regardless of attribution (within 5 working days of', 'knowledge of the event).', 'Unless otherwise noted, the electronic SAE application (eSAE) will be utilized for safety', 'reporting to the IND Office and MDACC IRB for participants enrolled at MDACC.', 'All life-threatening or fatal events, that are unexpected, and related to the study drug, must', 'have a written report submitted within 24 hours (next working day) of knowledge of the', 'event to the Safety Project Manager in the IND Office.', 'Serious adverse events will be captured from the time of the first protocol-specific', 'intervention, until 30 days after the last dose of drug, unless the participant withdraws', 'consent. Serious adverse events must be followed until clinical recovery is complete and', 'laboratory tests have returned to baseline, progression of the event has stabilized, or there', 'has been acceptable resolution of the event.', 'Additionally, any serious adverse events that occur after the 30 day time period that are', 'related to the study treatment must be reported to the IND Office. This may include the', 'development of a secondary malignancy.', 'Reporting to FDA:', 'Serious adverse events will be forwarded to FDA by the Investigator at UT MD Anderson', 'Cancer Center (Safety Project Manager IND Office) according to 21 CFR 312.32.', 'It is the responsibility of the PI and the research team to ensure serious adverse events are', 'reported according to the Code of Federal Regulations, Good Clinical Practices, the protocol', 'guidelines, UT MD Anderson Cancer Center, and Institutional Review Board policy.', '4.1.2 Case Report Form', 'In this study all AEs will be reported electronically via the AE Recording Form (PDMS/CORE)', '4.2', 'Investigator Communications with Onconova', 'Adverse Event Reporting to Supporting Company:', ""SAEs must be reported to Onconova within 24 hours of the study center's knowledge of the AE."", 'SAEs are to be emailed to USDrugSafety@onconova.us.', '4.3', 'Pregnancies', 'In pregnant rats, rigosertib was found to be fetotoxic (as evidenced by lower fetal weights) and', 'teratogenic (increased incidence of primarily craniofacial malformations). No maternal toxicity', 'was observed (see Rigosertib I IB). Pregnancies occurring between the signing of the ICF up to']"
34,page_35,"['2014-0546', 'August 7, 2017', 'Page 33 of 49', '30 days after the last dose of study drug must be reported on the Pregnancy Notification Form by', 'the investigational staff within 24 hr of their knowledge of the event. Any patient who becomes', 'pregnant during participation in this study must be promptly withdrawn from the study. These', 'patients will be asked to consent to allow their treating physician to provide Onconova with follow-', 'up information on the pregnancy itself and its outcome. Follow-up information regarding the', 'outcome of the pregnancy and any postnatal sequelae in the infant will be required.', '5.', 'REFERENCE LIST', 'Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera', 'and post-thrombocythemia myelofibrosis: a consensus statement from the international working', 'group for myelofibrosis research and treatment. Leukemia. 2008; 22:437-8', 'Chapman CM, Sun X, Roschewski M, et al. ON 01910.Na is selectively cytotoxic for chronic', 'lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition', 'and induction of oxydative stress. Clin Cancer Res. 2012; 18:1979-91.', 'Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom', 'assessment form total symptom score: prospective international assessment of an abbreviated', 'symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012; 30:4098-4103', 'Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University', 'School of Medicine (2007). ttp://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed', '2013/02/04.', 'Food & Drug Administration. Drug development and drug interactions: table of substrates,', 'inhibitors', 'and', 'inducers.', 'http://www.fda.gov/drugs/developmentapprovalprocess/', 'developmentresources/druginteractionslabeling/ucm093664.htm#PgpTransport', 'Jimeno A, Rubio-Viqueira B, Rajeshkumar NV, Chan A, Solomon A, Hidalgo M. A fine-needle', 'aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine', 'resistance in pancreatic cancer. Mol Cancer Ther. 2010; 9:311-8.', 'Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukemia', 'in adults. Br J Haematol. 1979; 43:185-90.', 'Mesa RA, Gotlib JR, Gupta V et al. Results using the modified myelofibrosis Symptom', 'Assessment Form (MFSAF v2.0) in Comfort I: a randomized, double-blind, phase III trial of', 'Jak 1/2 inhibitor ruxolitinib VS. Placebo in myelofibrosis. Poster 912; 16th Congress EHA; June', '2011', 'NCCN clinical practice guidelines in oncology (NCCN Guidelinesâ„¢M Myelodysplastic', 'syndromes. Version 2.2011.']"
35,page_36,"['2014-0546', 'August 7, 2017', 'Page 34 of 49', 'Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern', 'Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-55.', 'Olnes MJ, Shenoy A, Weinstein B et al. Directed therapy for patients with myelodysplastic', 'syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leukemia Res. 2012;', '36:982-9.', 'Prasad A, Park IW, Allen H, et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in', 'mantle cell lymphoma cells. Oncogene. 2009; 28:1518-28.', 'Raza A, Tycko B, Sangmin L, et al. Oral rigosertib (ON 01910.Na) treatment produces an', 'encouraging rate of transfusion independence in lower risk myelodysplastic syndrome (MDS)', 'patients; a genomic methylation profile is associated with responses. ASH 2013, New Orleans,', 'LA. Abstract #2745.', 'Reddy MV, Mallireddigari MR, Cosenza SC, et al. Design, synthesis, and biological evaluation', 'of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem. 2008; 51: 86-100.', ""Rigosertib (ON 01910.Na) Investigator's Brochure. Edition 19, November 20, 2013."", 'Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health', 'Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary', 'myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;', '110:1092-7.', 'Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International', 'Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and', 'European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395-8.', 'Thiele J, Kvasnicka HM, Facchetti F, Franco V, Ven der Walt J, Orazi A. et al. European', 'consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica.', '2005; 90:1128.', 'Vardiman JW, Thiele J, Arber DA, et al. The 2008 revisions of the World Health Organization', '(WHO) classification of myeloid neoplasms and acute leukemia: rationale and important', 'changes. Blood. 2009;114:937-51.']"
36,page_37,"['2014-0546', 'August 7, 2017', 'Page 35 of 49', '6.', 'APPENDICES']"
37,page_38,"['2014-0546', 'August 7, 2017', 'Page 36 of 49', 'Appendix 1: WHO Criteria for Diagnosis of Primary Myelofibrosis, Essential Thrombocythemia, and', 'Polycythemia Vera', 'Reference: Vardiman 2009', 'Criteria for Primary Myelofibrosis(PMF)', 'Diagnosis requires meeting all 3 major criteria and 2 minor criteria.', 'Major Criteria', '1.', 'Presence of megakaryocyte proliferation and atypia, (a) usually accompanied by either reticulin or', 'collagen fibrosis', 'or,', 'in the absence of significant reticulin fibrosis, the megakaryocyte changes must be accompanied by an', 'increased bone marrow cellularity characterized by granulocytic proliferation and often decreased', 'erythropoiesis (ie, prefibrotic cellular-phase disease)', '2.', 'Not meeting WHO criteria for polycythemia vera, (b) BCR-ABLI-positive chronic myelogenous', 'leukemia, (c) myelodysplastic syndrome, (d) or other myeloid disorders', '3.', 'Demonstration of JAK2 V617F or other clonal marker (eg, MPLW515K/L),', 'or,', 'in the absence of the above clonal markers, no evidence that bone marrow fibrosis is secondary to', 'infection, autoimmune disorder or other chronic inflammatory condition, hairy cell leukemia or', 'other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) myelopathies(e', 'Minor criteria', '1. Leukoerythroblastosis! (f)', '2. Increase in serum lactate dehydrogenase level(f)', '3. Anemia (f)', '4.', 'Palpable splenomegaly\\ (f)', '(a)', 'Small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous, or irregularly', 'folded nuclei and dense clustering.', '(b)', 'Requires the failure of iron replacement therapy to increase hemoglobin level to the polycythemia vera range in the', 'presence of decreased serum ferritin. Exclusion of polycythemia vera is based on hemoglobin and hematocrit levels.', 'Red cell mass measurement is not required.', '(c)', 'Requires the absence of BCR-ABL1.', '(d)', 'Requires the absence of dyserythropoiesis and dysgranulopoiesis.', '(e)', 'It should be noted that patients with conditions associated with reactive myelofibrosis are not immune to primary', 'myelofibrosis, and the diagnosis should be considered in such cases if other criteria are met.', '(f)', 'Degree of abnormality could be borderline or marked.']"
38,page_39,"['2014-0546', 'August 7, 2017', 'Page 37 of 49', 'Criteria for Essential Thrombocythemia (ET)', 'Diagnosis requires meeting all 4 criteria', '1.', 'Sustained platelet count > 450 X 109/L(a)', '2. Bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic lineage with', 'increased numbers of enlarged, mature megakaryocytes. No significant increase or left-shift of', 'neutrophil granulopoiesis or erythropoiesis.', '3. Not meeting WHO criteria for polycythemia vera, (b) primary myelofibrosis,(c) BCR-ABLI-positive', 'CML, (d) or myelodysplastic syndrome, (e) or other myeloid neoplasm.', '4.', 'Demonstration of JAK2 V617F or other clonal marker, or in the absence of JAK2 V617F, no evidence', 'of reactive thrombocytosis(1', 'ET = essential thrombocythemia; BM = bone marrow; WHO = World Health Organization; CML = chronic myelogenous', 'leukemia.', '(a)', 'Sustained during the work-up process.', '(b)', 'Requires the failure of iron replacement therapy to increase hemoglobin level to the polycythemia vera range in the', 'presence of decreased serum ferritin. Exclusion of polycythemia vera is based on hemoglobin and hematocrit levels,', 'and red cell mass measurement is not required.', '(c)', 'Requires the absence of relevant reticulin fibrosis, collagen fibrosis, peripheral blood leukoerythroblastosis, or', 'markedly hypercellular marrow accompanied by megakaryocyte morphology that is typical for primary', 'myelofibrosis-small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic,', 'bulbous, or irregularly folded nuclei and dense clustering.', '(d)', 'Requires the absence of BCR-ABL1.', '(e)', 'Requires the absence of dyserythropoiesis and dysgranulopoiesis.', '(f)', 'Causes of reactive thrombocytosis include iron deficiency, splenectomy, surgery, infection, inflammation,', 'connective tissue disease, metastatic cancer, and lymphoproliferative disorders. However, the presence of a', 'condition associated with reactive thrombocytosis does not exclude the possibility of ET if other criteria are met.', 'Criteria for Polycythemia Vera (PV)', 'Diagnosis requires the presence of both major criteria and 1 minor criterion or the presence of the first', 'major criterion together with 2 minor criteria', 'Major Criteria', '1. Hemoglobin > 18.5 g/dL in men, 16.5 g/dL in women or other evidence of increased red cell volume*', '2.', 'Presence of JAK2 V617F or other functionally similar mutation such as JAK2 exon 12 mutation', 'Minor criteria', '1. Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with', 'prominent erythroid, granulocytic, and megakaryocytic proliferation', '2. Serum erythropoietin level below the reference range for normal', '3.', 'Endogenous erythroid colony formation in vitro', '*Hemoglobin or hematocrit > 99th percentile of method-specific reference range for age, sex, altitude of residence or', 'hemoglobin > 17 g/dL in men, 15 g/dL in women if associated with a documented and sustained increase of at least 2 g/dL', ""from a person's baseline value that cannot be attributed to correction of iron deficiency or elevated red cell mass > 25%"", 'above mean normal predicted value.']"
39,page_40,"['2014-0546', 'August 7, 2017', 'Page 38 of 49', 'Appendix 2: 2008 IWG-MRT Diagnosis Criteria for Post-Polycythemia Vera and Post-Essential', 'Thrombocythemia Myelofibrosis', 'Reference: Barosi 2008', 'IWG-MRT Recommended Criteria for Post-Polycythemia Vera (PV) Myelofibrosis (MF) and', 'Post-Essential Thrombocythemia (ET) MF', 'Criteria for Post-PV MF', 'Required Criteria:', '1.', 'Documentation of a previous diagnosis of polycythemia vera as defined by the WHO criteria', '(Tefferi 2007 and Error! Reference source not found.)', '2. Bone marrow fibrosis grade 2-3 (on a 0-3 scale) (Thiele 2005)(a or grade 3-4 (on a 0-4 scale)', '(Manoharan 1979) (a)', 'Additional Criteria (two are required):', '1.', 'Anemia(b) or sustained loss of requirement of either phlebotomy (in the absence of cytoreductive', 'therapy) or cytoreductive treatment for erythrocytosis', '2.', 'A leukoerythroblastic peripheral blood picture', '3. Increasing splenomegaly defined as either an increase in palpable splenomegaly of > 5 cm', '(distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable', 'splenomegaly', '4.', 'Development of > 1 of 3 constitutional symptoms: > 10% weight loss in 6 months, night sweats,', 'unexplained fever (> 37.5Â°C)', 'Criteria for Post-ET MF', 'Required Criteria:', '1. Documentation of a previous diagnosis of essential thrombocythemia as defined by the WHO', 'criteria (Tefferi 2007)', '2. Bone marrow fibrosis grade 2-3 (on 0-3 scale) (Thiele 2005) (a) or grade 3-4 (on 0-4 scale)', '(Manoharan 1979(a)', 'Additional Criteria (2 are required):', '1. Anemia (b) and a > 2 mg/mL (Tefferi 2007) decrease from baseline hemoglobin level', '2.', 'A leukoerythroblastic peripheral blood picture', '3. Increasing splenomegaly defined as either an increase in palpable splenomegaly of > 5 cm', '(distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable', 'splenomegaly', '4. Increased lactate dehydrogenase (LDH) (above reference level)']"
40,page_41,"['2014-0546', 'August 7, 2017', 'Page 39 of 49', 'IWG-MRT Recommended Criteria for Post-Polycythemia Vera (PV) Myelofibrosis (MF) and', 'Post-Essential Thrombocythemia (ET) MF', '5. Development of > 1 of 3 constitutional symptoms: > 10% weight loss in 6 months, night sweats,', 'unexplained fever (> 37.5C)', 'IWG-MRT = International Working Group for Myelofibrosis Research and Treatment; LDH = lactate', 'dehydrogenase;', '(a)', 'Grade 2-3 according to the European classification: diffuse, often coarse fiber network with no evidence', 'of collagenization (negative trichrome stain) or diffuse, coarse fiber network with areas of', 'collagenization (positive trichrome stain). Grade 3-4 according to the standard classification: diffuse and', 'dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen', 'and/or focal osteosclerosis or diffuse and dense increase in reticulin with extensive intersections with', 'coarse bundles of collagen, often associated with significant osteosclerosis', '(b)', 'Below the reference range for appropriate age, sex, gender and altitude considerations']"
41,page_42,"['2014-0546', 'August 7, 2017', 'Page 40 of 49', 'Appendix 3: Eastern Cooperative Oncology Group (ECOG) Performance Status', 'The ECOG toxicity and response criteria are summarized below (Oken 1982).', 'ECOG Score', 'Description', '0', 'Fully active, able to carry on all pre-disease performance without restriction.', '1', 'Restricted in physically strenuous activity but ambulatory and able to carry out', 'work of a light or sedentary nature, eg, light housework, office work.', '2', 'Ambulatory and capable of all self-care but unable to carry out any work', 'activities. Up and about more than 50% of waking hours.', '3', 'Capable of only limited self-care, confined to bed or chair more than 50% of', 'waking hours.', '4', 'Completely disabled. Cannot carry on any self-care. Totally confined to bed or', 'chair.']"
42,page_43,"['2014-0546', 'August 7, 2017', 'Page 41 of 49', 'Appendix 4: 2013 IWG-MRT Revised Response Criteria for Myelofibrosis', 'Reference: Tefferi 2013', 'Revised IWG-MRT and ELN Response Criteria for Myelofibrosis', 'Required Criteria (For all response categories, benefit must last for', 'Response Categories', '12 weeks to qualify as a response)', 'Complete response (CR)', 'Bone marrow(1): Age-adjusted normocellularity; < 5% blasts; VI Grade 1', 'MF(2) and', 'Peripheral blood: Hemoglobin > 100 g/L and < ULN; neutrophil count', '> 1 X 109/L and < ULN; platelet count > 100 X 109/L and < ULN; < 2%', 'immature myeloid cells(3) and', 'Clinical: Resolution of disease symptoms; spleen and liver not palpable; no', 'evidence of EMH', 'Partial response (PR)', 'Peripheral blood: Hemoglobin > 100 g/L and < ULN; neutrophil count', '1 X 109/L and < UNL; platelet count > 100 x 109/L and < ULN; < 2%', 'immature myeloid cells(3)', 'and', 'Clinical: resolution of disease symptoms; spleen and liver not palpable; no', 'evidence of EMH or', 'Bone marrow(1): Age-adjusted normocellularity; < 5% blasts; Grade 1', 'MF(2) and peripheral blood: Hemoglobin > 85 but < 100 g/L and < ULN;', 'neutrophil count > 1 X 109/L and < ULN; platelet count > 50, but', ""< 100 x 109/L and < ULN; < 2% immature myeloid cells' (3) and"", 'Clinical: Resolution of disease symptoms; spleen and liver not palpable; no', 'evidence of EMH', 'Clinical improvement (CI)', 'The achievement of anemia, spleen or symptoms response without', 'progressive disease or increase in severity of anemia, thrombocytopenia,', 'or', 'neutropenia (4)', 'Anemia response', 'Anemia response is a composite endpoint defined as an increase in', 'hemoglobin (hemoglobin response; defined below) in a subject with anemia', '(5) OR becoming RBC-transfusion-independent in a subject who is RBC-', 'transfusion-dependent (6) defined as follows:', 'Hemoglobin-response is defined as an increase in hemoglobin level of', '>1.5 g/L (compared to baseline) on every determination consecutively', 'for a >84 d interval, without RBC-transfusions.', 'RBC-transfusion-independence is defined as no RBC-transfusion', 'in', 'any ""rolling"" 84 day interval during the treatment period, in patients', 'who were RBC-transfusion dependent at enrollment.', 'Spleen responsel', 'A baseline splenomegaly that is palpable at 5-10 cm, below the LCM,', 'becomes not palpable (8)', 'A baseline splenomegaly that is palpable at > 10 cm, below the LCM,', 'decreases by > 50%(8)', 'A baseline splenomegaly that is palpable at < 5 cm, below the LCM, is not']"
43,page_44,"['2014-0546', 'August 7, 2017', 'Page 42 of 49', 'Revised IWG-MRT and ELN Response Criteria for Myelofibrosis', 'eligible for spleen response', 'A spleen response requires confirmation by MRI or computed tomography', 'showing > 35% spleen volume reduction', 'Symptoms response', 'A > 50% reduction in the MPN-SAF TSS(9)', 'Progressive disease (PD) (10)', 'Appearance of a new splenomegaly that is palpable at least 5 cm below the', 'LCM or', 'A> 100% increase in palpable distance, below LCM, for baseline', 'splenomegaly of 5-10 cm or', 'A 50% increase in palpable distance, below LCM, for baseline', 'splenomegaly of > 10 cm or', 'Leukemic transformation confirmed by a bone marrow blast count of > 20%', 'or', 'A peripheral blood blast content of > 20% associated with an absolute blast', 'count of > 1 X 109/L that lasts for at least 2 weeks', 'Stable disease (SD)', 'Belonging to none of the above listed response categories', 'Relapse', 'No longer meeting criteria for at least CI after achieving CR, PR, or CI, or', 'Loss of anemia response persisting for at least 1 month or', 'Loss of spleen response persisting for at least 1 month', 'Recommendations for assessing treatment-induced cytogenetic and molecular changes', 'Cytogenetic remission', 'At least 10 metaphases must be analyzed for cytogenetic response', 'evaluation and requires confirmation by repeat testing within a 6-months', 'window', 'CR: eradication of a preexisting abnormality', 'PR: > 50% reduction in abnormal metaphases (PR applies only to patients', 'with at least 10 abnormal metaphases at baseline)', 'Molecular remission', 'Molecular response evaluation must be analyzed in peripheral blood', 'granulocytes and requires confirmation by repeat testing within 6 months', 'window', 'CR: Eradication of a pre-existing abnormality', 'PR: > 50% decrease in allele burden (PR applies only to patients with at', 'least 20% mutant allele burden at baseline)', 'Cytogenetic/molecular relapse', 'Re-emergence of a pre-existing cytogenetic or molecular abnormality that is', 'confirmed by repeat testing', 'EMH = extramedullar hematopoiesis (no evidence of EMH implies the absence of pathology- or imaging study-proven', 'nonhepatosplenic EMH); LCM = left costal margin; ULN = upper limit of normal; MPN-SAF TSS = myeloproliferative', 'neoplasm symptom assessment form total symptom score;.', '(1)', 'Baseline and post-treatment bone marrow slides are to be interpreted at one sitting by a central review process.', 'Cytogenetic and molecular responses are not required for CR assignment.', '(2)', 'Grading of MF is according to the European classification (Thiele 2005). It is underscored that the consensus', 'definition of a CR bone marrow is to be used in only those patients in whom all other criteria are met, including', 'resolution of leukoerythroblastosis. It should also be noted that it was a particularly difficult task for the working group', 'to reach a consensus regarding what represents a complete histologic remission.', '(3)', 'Immature myeloid cells constitute blasts + promyelocytes + myelocytes + metamyelocytes + nucleated red blood cells.', 'In splenectomized patients, < 5% immature myeloid cells is allowed.']"
44,page_45,"['2014-0546', 'August 7, 2017', 'Page 43 of 49', 'Revised IWG-MRT and ELN Response Criteria for Myelofibrosis', '(4)', 'See above for definitions of anemia response, spleen response, and progressive disease. Increase in severity of anemia', 'constitutes the occurrence of new transfusion dependency or a > 20 g/L decrease in hemoglobin level from', 'pretreatment baseline that lasts for at least 12 weeks. Increase in severity of thrombocytopenia or neutropenia is', 'defined as a 2-grade decline, from pretreatment baseline, in platelet count or absolute neutrophil count, according to', 'the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In addition, assignment to CI requires a', 'minimum platelet count of > 25,000 x 109/L and absolute neutrophil count of > 0.5 x 109/L.', '(5)', 'Applicable only to patients with baseline hemoglobin of < 100 g/L. In patients not meeting the strict criteria for', 'transfusion dependency at the time of study enrollment (see as follows), but have received transfusions within the', 'previous month, the pretransfusion hemoglobin level should be used as the baseline.', '(6) Transfusion dependency before study enrollment is defined as transfusions of at least 6 units of packed red blood cells', '(PRBC), in the 12 weeks prior to study enrollment, for a hemoglobin level of < 85 g/L, in the absence of bleeding or', 'treatment-induced anemia. In addition, the most recent transfusion episode must have occurred in the 28 days prior to', 'study enrollment. Response in transfusion-dependent patients requires absence of any PRBC transfusions during any', 'consecutive ""rolling"" 12-week interval during the treatment phase, capped by a hemoglobin level of > 85 g/L.', '(7)', 'In splenectomized patients, palpable hepatomegaly is substituted with the same measurement strategy.', '(8)', 'Spleen or liver responses must be confirmed by imaging studies where a > 35% reduction in spleen volume, as', 'assessed by MRI or CT, is required. Furthermore, a > 35% volume reduction in the spleen or liver, by MRI or CT,', 'constitutes a response regardless of what is reported with physical examination.', '(9)', 'Symptoms are evaluated by the MPN-SAF TSS (Emanuel 2012). The MPN-SAF TSS is assessed by the patients', 'themselves and this includes fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain,', 'abdominal discomfort, weight loss, and fevers. Scoring is from 0 (absent/as good as it can be) to 10 (worst', 'imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0-100', 'scale). Symptoms response requires > 50% reduction in the MPN-SAF TSS.', '(10) Progressive disease assignment for splenomegaly requires confirmation by MRI or CT showing a > 25% increase in', 'spleen volume from baseline. Baseline values for both physical examination and imaging studies refer to pretreatment', 'baseline and not to post-treatment measurements.']"
45,page_46,"['2014-0546', 'August 7, 2017', 'Page 44 of 49', 'Appendix 5: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-', 'SAF TSS)', 'MRN', 'Name', '1 to 10 (0 if absent) ranking', 'Symptom', '1 is most favorable and 10 least favorable', 'Please rate your fatigue (weariness,', 'tiredness) by circling the one number', '(No fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)', 'that best describes your WORST level', 'of fatigue during the past 24 hours', 'Circle the one number that describes how, during the past week, much', 'difficulty you have had with each of the following symptoms', 'Numbess/Tingling in hands and feet', '(Absent) 0 1 2 3 4 5 6 7 8 9 10', '(Worst Imaginable)', 'Night Sweats', '(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)', 'Itching (pruritus)', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', 'Bone Pain', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', '(Diffuse - not joint pain or arthritis)', 'Fever (>100F)', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', 'Unintentional weight loss last 6', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', 'months', 'Filling up quickly when you eat', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', '(Early satiety)', 'Abdominal Discomfort', '(Absent)', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '(Worst Imaginable)', 'Inactivity', '(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)', 'Problems with concentration -', '(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)', 'compared to prior to my MPD']"
46,page_47,"['2014-0546', 'August 7, 2017', 'Page 45 of 49', 'Appendix 6: Schedule of Events and Procedures', 'Schedule of Events and Procedures', 'Q4W for', '12 Wk', 'Week 24', 'End-of-study/', 'Baseline/', 'then', 'and', 'Early', 'Tests/Evaluations', 'Screening', 'C1D1b', 'QWb', 'Q8Wb', 'Week 48b', 'Withdrawal', 'Informed consent', 'X', 'Demographics', 'X', 'Inclusion/exclusion criteria', 'X', 'Medical historyd', 'X', 'X', 'Prior & current therapy d', 'X', 'X', 'Concomitant medications', 'X', 'X', 'X', 'Transfusion historye', 'X', 'X', 'X', 'X', 'Physical examination', 'X', 'xf', 'X', 'X', 'ECOG performance status', 'X', 'xf', 'X', 'X', 'Vital signs', 'X', 'X', 'X', 'X', 'Height and weightg', 'X', 'X', 'X', 'X', '12-lead ECG', 'X', 'CBC with differentialh', 'X', 'xf', 'X', 'X', 'Serum chemistry panelÂ¹', 'X', 'xf', 'X', 'X', 'Serum erythropoietin', 'X', 'Serum ferritin', 'X', 'Blood/urine pregnancy testl', 'X', 'X', 'X', 'Urinalysis', 'X', 'xf', 'X', 'X', 'BM aspirate and/or biopsy', 'X', 'X', 'and cytogenetics', 'QOL questionnaire', 'X', 'X', '(MPN-SAF-TSS)', 'Spleen volume (MRI or CT)', 'X', 'X', 'in patients with palpable', 'splenomegaly at baseline', 'Blood PK samplesm', 'X', 'Xm', 'Study drug dispensing', 'X', 'X', 'Assessment of compliance', 'X']"
47,page_48,"['2014-0546', 'August 7, 2017', 'Page 46 of 49', 'Schedule of Events and Procedures', 'Q4W for', '12 Wk', 'Week 24', 'End-of-study/', 'Baseline/', 'then', 'and', 'Early', 'Tests/Evaluations', 'Screening', 'C1D1b', 'QWb', 'Q8Wb', 'Week 48b', 'Withdrawal', 'Adverse events1', 'X', 'X', 'X', 'a', 'Screening procedures will occur up to 14 days before Baseline/C1D1 visit, except for urine pregnancy test (to be done', 'within 7 days prior to Baseline/C1D1 visit). Bone marrow aspirates and biopsies performed up to 6 weeks before', 'Baseline/C1D1 visit do not need to be repeated. JAK2V617F allele burden measurement in BM samples, if not done', 'within 6 months prior to Screening, must be provided with the Screening BM biopsy/aspirate report.', 'b', 'A 2-day window is allowed for Baseline/C1D1 and QW; a 5-day window for Q4W and Q8W visits. A 1-week window is', 'allowed for Weeks 24 and 48 visits.', 'c', 'The end-of-study/early withdrawal procedures should be performed 30 days after study completion. If a study procedure', 'cannot be performed on the scheduled day, the procedure must be performed within 1 week.', 'd', 'Includes date and diagnosis of MF and JAK2V617F status. The last available karyotype report prior to Screening should', 'be collected. Prior treatment with ruxolitinib if applicable needs to be documented. Medical and medication history should', 'be updated at Baseline/C1D1 visit.', 'e', 'This includes number and dates of PRBC and PLT units administered within the past 12 weeks prior to enrollment, and', 'Hgb and PLT values prior to transfusion.', 'f', 'Does not need to be repeated at Baseline/C1D1 visit if Screening took place within 72 hours.', 'g Height measured at Screening only.', 'h', ""Automated and/or manual differential per institution's standard; the method should be consistent throughout the study."", 'i', 'Includes serum albumin, total protein, total bilirubin, direct bilirubin (if total bilirubin > ULN), ALT, AST, LDH, alkaline', 'phosphatase, bicarbonate, sodium, potassium, chloride, serum creatinine, BUN, calcium, phosphorus, uric acid, and', 'glucose. Note: If a patient develops >Grade 3 hyponatremia, rigosertib will not be administered and serum and urine', 'osmolality, serum albumin, BUN, creatinine, and serum and urinary sodium will be measured to assist in the medical', 'management of hyponatremia. Additional tests may be carried out as clinically warranted.', 'j', 'Blood or urine pregnancy test in female patients of childbearing potential only; must be completed within 7 days prior to', 'Baseline/C1D1 visit. Pregnancy tests must have sufficient sensitivity (ie, at least 25 mIU/mL) to guarantee positive', 'identification of pregnancy.', 'k', 'Includes glucose, protein, white blood cells (WBC), blood/occult blood, ketone, pH and specific gravity, and crystals.', '1', 'Bone marrow aspirate and/or biopsy and cytogenetics must be performed within 6 weeks prior to Screening visit;', 'JAK2 V617F allele burden measurement in BM samples, if not done within 6 months prior to Screening, must be provided', 'with the Screening BM biopsy/aspirate report. BM aspirate and/or biopsy will be performed every 12 weeks only in', 'patients with more than 5% pre-treatment BMBL.', 'm', 'Blood samples for Population PK analysis will be obtained in all patients at Baseline/C1D1 visit 1 hr after rigosertib', 'administration (morning dose), and on Day 28 (+/- 5 days) from start of therapy at predose and 1 hr after administration', 'of', 'rigosertib (morning dose).', 'n AEs will be monitored from the time of the first protocol-specific intervention up to 30 days after the last dose of', 'rigosertib.']"
48,page_49,"['2014-0546', 'August 7, 2017', 'Page 47 of 49', 'Appendix 7: List of Clinical Laboratory Tests', 'Serum Chemistry Panel :', 'Complete Blood Count with Differential:', 'Serum albumin', 'White blood cells (WBC)', 'Total protein', 'Neutrophils (absolute count)', 'Total bilirubin', 'Lymphocytes (absolute count)', 'Direct bilirubin (if total bilirubin > ULN only)', 'Monocytes (absolute count)', 'Aspartate transaminase (AST)', 'Basophils (absolute count)', 'Alanine transaminase (ALT)', 'Eosinophils (absolute count)', 'Lactate dehydrogenase (LDH)', 'Red blood cells (RBC)', 'Alkaline phosphatase', 'Hematocrit', 'Bicarbonate', 'Hemoglobin (Hgb)', 'Sodium', 'Mean corpuscular volume (MCV)', 'Potassium', 'Mean corpuscular hemoglobin (MCH)', 'Chloride', 'Mean corpuscular hemoglobin concentration (MCHC)', 'Serum creatinine', 'Platelets (PLT)', 'BUN', 'Mean platelet volume', 'Glucose', 'Calcium', 'Phosphorus', 'Uric acid', 'Hyponatremia Panel (if Grade 3 Hyponatremia):', 'Urinalysis:', 'Serum osmolality', 'pH', 'Urine osmolality', 'Specific gravity', 'Serum albumin', 'Protein', 'BUN', 'Glucose', 'Serum creatinine', 'WBC', 'Serum sodium', 'Blood/occult blood', 'Urinary sodium', 'Ketone', 'Crystals (microscopic analysis)', 'Other Serum Laboratory Tests:', 'Pregnancy test (if childbearing potential):', 'Blood or urine pregnancy tests', 'Serum endogenous erythropoietin', 'Serum ferritin']"
49,page_50,"['2014-0546', 'August 7, 2017', 'Page 48 of 49', 'Appendix 8: List of Potential Substrates of CYP 2C8 and 2C9', 'Reference: Flockhart 2007', 'Substrates of CYP 2C8 and 2C9 include, but are not limited to, drugs below:', '2C8 Substrates', '2C9 Substrates', 'amodiaquine', 'NSAIDs:', 'cerivastatin', 'diclofenac', 'paclitaxel', 'ibuprofen', 'repaglinide', 'lornoxicam', 'sorafenib', 'meloxicam', 'torsemide', 'S-naproxen->Nor', 'piroxicam', 'suprofen', 'Oral Hypoglycemic Agents:', 'tolbutamide', 'glipizide', 'Angiotensin II Blockers:', 'losartan', 'irbesartan', 'Sulfonylureas:', 'glyburide', 'glibenclamide', 'glipizide', 'glimepiride', 'tolbutamide', 'Others:', 'amitriptyline', 'celecoxib', 'fluoxetine', 'fluvastatin', 'glyburide', 'nateglinide', 'phenytoin-4-OH2', 'rosiglitazone', 'tamoxifen', 'torsemide', 'S-warfarin', 'Sulfamethoxazole']"
50,page_51,"['2014-0546', 'August 7, 2017', 'Page 49 of 49', 'Appendix 9: List of Potential Inhibitors of P-gp', 'Reference: FDA Guidance', 'Examples of In Vivo Inhibitors of Human Transporter P-gP (MDR1)', 'Amiodarone', 'Azithromycin', 'Captopril', 'Carvedilol', 'Clarithromycin', 'Conivaptan', 'Cyclosporine', 'Diltiazem', 'Dronedarone', 'Erythromycin', 'Felodipine', 'Itraconazole', 'Ketoconazole', 'Lopinavir & Ritonavir', 'Quercetin', 'Quinidine', 'Ranolazine', 'Ticagrelor', 'Verapamil']"
